

Supplementary material to “**The epidemiology and direct medical costs of diseases associated with human papillomavirus infection among men in Manitoba, Canada**” by Christiaan H. Righolt, Gurpreet Pabla, Salaheddin M. Mahmud

<b>Supplementary tables</b> .....	12
Supplementary Table 1: ICD-O-3 topography and morphology codes for HPV-related cancers of interest .....	12
Supplementary Table 2: Tariff codes used to identify male patients with anogenital warts in the medical claims [1] .....	12
Supplementary Table 3: Identification of hospitalized patients with anogenital warts [1] .....	12
Supplementary Table 4: ICD-9-CM procedure codes used to assist in the identification of a male with anogenital warts [1].....	13
Supplementary Table 5: ICD-10 procedure codes used to assist in the identification of a male with anogenital warts [1] .....	13
Supplementary Table 6: Tariff codes for treatment of anogenital warts used to assist in the identification of a male with anogenital warts [1] .....	14
Supplementary Table 7 Fraction of HPV-related diseases attributable to the HPV types included in different HPV vaccines [2].....	15
Supplementary Table 8 Overall fraction of HPV-related diseases attributable to any HPV type .....	15
<b>Incidence Rates</b> .....	16
Supplementary Table 9 Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by regional health authority of residence (1997 - 2016).....	16
Supplementary Table 10 Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by Winnipeg region of residence (1997 - 2016).....	16
Supplementary Table 11 Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by year of diagnosis. ....	17
Supplementary Table 12 Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by age group and regional health authority and Winnipeg region of residence (1997 - 2016). ....	18
<b>Incidence Rates by age and year of diagnosis</b> .....	19
Supplementary Table 13 Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by age group and year of diagnosis. ....	19
Supplementary Table 14 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma <i>in situ</i> among Manitoba males by age group and year of diagnosis. ....	19
Supplementary Table 15 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by age group and year of diagnosis. ....	19
Supplementary Table 16 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by age group and year of diagnosis. ....	21

Supplementary Table 17 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by age group and year of diagnosis. .... 21

Supplementary Table 18 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by age group and year of diagnosis. .... 21

Supplementary Table 19 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by age group and year of diagnosis. .... 23

Incidence Rates by birth year cohort and year of diagnosis ..... 24

Supplementary Table 20 Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by birth year and year of diagnosis. .... 24

Supplementary Table 21 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma *in situ* among Manitoba males by birth year and year of diagnosis. .... 24

Supplementary Table 22 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by birth year and year of diagnosis. 25

Supplementary Table 23 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by birth year and year of diagnosis. .... 25

Supplementary Table 24 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by birth year and year of diagnosis. .... 26

Supplementary Table 25 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by birth year and year of diagnosis. .... 26

Supplementary Table 26 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by birth year and year of diagnosis. .... 27

Incidence Rates by birth year cohort and age ..... 28

Supplementary Table 27 Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by birth year and age group. .... 28

Supplementary Table 28 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma *in situ* among Manitoba males by birth year and age group. .... 28

Supplementary Table 29 Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by birth year and age group. .... 29

Supplementary Table 30 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by birth year and age group. .... 29

Supplementary Table 31 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by birth year and age group. .... 30

Supplementary Table 32 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by birth year and age group. .... 30

Supplementary Table 33 Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by birth year and age group. .... 31

Costing ..... 32

Supplementary Table 34 Total net direct medical cost <sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males (1997-2015).....	32
Supplementary Table 35 Total net direct medical cost <sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	32
Supplementary Table 36 Total net direct medical cost <sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority of residence (1997-2015).....	34
Supplementary Table 37 Total net direct medical cost <sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by Winnipeg region of residence (1997-2015).....	34
Supplementary Table 38 Total net direct medical cost <sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015).....	36
Supplementary Table 39 Average of net direct medical cost of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by successive 90-day periods before and after diagnosis (1997-2015).....	38
Supplementary Table 40 Median of net direct medical cost of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by successive 90-day periods before and after diagnosis (1997-2015).....	39
<b><u>Net cost by age</u></b> .....	40
Supplementary Table 41 Distribution of net direct medical cost <sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	40
Supplementary Table 42 Distribution of net direct medical cost <sup>1</sup> of HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	40
Supplementary Table 43 Distribution of net direct medical cost <sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	40
Supplementary Table 44 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	42
Supplementary Table 45 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	42
Supplementary Table 46 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	42
Supplementary Table 47 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015).....	43
<b><u>Net cost by regional health authority and Winnipeg region of residence</u></b> .....	44

Supplementary Table 48 Distribution of net direct medical cost <sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015) .....	44
Supplementary Table 49 Distribution of net direct medical cost <sup>1</sup> of HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015) .....	44
Supplementary Table 50 Distribution of net direct medical cost <sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015) .....	45
Supplementary Table 51 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015) .....	45
Supplementary Table 52 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).....	46
Supplementary Table 53 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).....	46
Supplementary Table 54 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015) .....	47
<b>Net cost by year of diagnosis</b> .....	<b>48</b>
Supplementary Table 55 Distribution of net direct medical cost <sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015) .....	48
Supplementary Table 56 Distribution of net direct medical cost <sup>1</sup> of HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015).....	49
Supplementary Table 57 Distribution of net direct medical cost <sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015) .....	50
Supplementary Table 58 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015) .....	51
Supplementary Table 59 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015).....	52
Supplementary Table 60 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015).....	53
Supplementary Table 61 Distribution of net direct medical cost <sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015) .....	54
<b>Healthcare utilization</b> .....	<b>55</b>

Supplementary Table 62 Average number of healthcare encounters <sup>1</sup> (per year) of HPV-related disease patients and their matches among Manitoba males (1997-2015) .....	55
Supplementary Table 63 Excess number of healthcare encounters <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males (1997-2015).....	56
Supplementary Table 64 Distribution of excess number of healthcare encounters <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males (1997-2015) .....	57
<b><u>Excess healthcare utilization by age</u></b> .....	59
Supplementary Table 65 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	59
Supplementary Table 66 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	59
Supplementary Table 67 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015).....	59
Supplementary Table 68 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	60
Supplementary Table 69 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	60
Supplementary Table 70 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by age group (1997-2015).....	60
Supplementary Table 71 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	62
Supplementary Table 72 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	62
Supplementary Table 73 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	62
Supplementary Table 74 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	64
Supplementary Table 75 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	64
Supplementary Table 76 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	64

Supplementary Table 77 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	66
Supplementary Table 78 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	66
Supplementary Table 79 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	66
Supplementary Table 80 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	67
Supplementary Table 81 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	67
Supplementary Table 82 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	67
Supplementary Table 83 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	68
Supplementary Table 84 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	69
Supplementary Table 85 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	69
Supplementary Table 86 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	69
Supplementary Table 87 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	70
Supplementary Table 88 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	70
Supplementary Table 89 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	70
Supplementary Table 90 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	71

Supplementary Table 91 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	71
Supplementary Table 92 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015). .....	71
<b><u>Excess healthcare utilization by regional health authority and Winnipeg region of residence</u></b> .....	<b>73</b>
Supplementary Table 93 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	73
Supplementary Table 94 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	73
Supplementary Table 95 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	74
Supplementary Table 96 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	74
Supplementary Table 97 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	75
Supplementary Table 98 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	75
Supplementary Table 99 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	76
Supplementary Table 100 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	76
Supplementary Table 101 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	77
Supplementary Table 102 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	77
Supplementary Table 103 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	78
Supplementary Table 104 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). .....	78

Supplementary Table 105 Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 79

Supplementary Table 106 Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 79

Supplementary Table 107 Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 80

Supplementary Table 108 Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 80

Supplementary Table 109 Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 81

Supplementary Table 110 Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 81

Supplementary Table 111 Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 82

Supplementary Table 112 Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 82

Supplementary Table 113 Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 83

Supplementary Table 114 Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 83

Supplementary Table 115 Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 84

Supplementary Table 116 Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 84

Supplementary Table 117 Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 85

Supplementary Table 118 Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015). ..... 85



Supplementary Table 119 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).....	86
Supplementary Table 120 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).....	86
<b>Excess healthcare utilization by year of diagnosis</b> .....	<b>87</b>
Supplementary Table 121 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	87
Supplementary Table 122 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	88
Supplementary Table 123 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	89
Supplementary Table 124 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	90
Supplementary Table 125 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	91
Supplementary Table 126 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	92
Supplementary Table 127 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	93
Supplementary Table 128 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related carcinoma <i>in situ</i> (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	94
Supplementary Table 129 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	95
Supplementary Table 130 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	96
Supplementary Table 131 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	97
Supplementary Table 132 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	98

Supplementary Table 133 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	99
Supplementary Table 134 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	100
Supplementary Table 135 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	101
Supplementary Table 136 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	102
Supplementary Table 137 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	103
Supplementary Table 138 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	104
Supplementary Table 139 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	105
Supplementary Table 140 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	106
Supplementary Table 141 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	107
Supplementary Table 142 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	108
Supplementary Table 143 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	109
Supplementary Table 144 Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	110
Supplementary Table 145 Distribution of excess number of clinician visits <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	111
Supplementary Table 146 Distribution of excess number of hospital admissions <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015). .....	112

Supplementary Table 147 Distribution of excess number of ER visits <sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	113
Supplementary Table 148 invasive cancer of the penis Distribution of excess number of prescriptions <sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).....	114
<b><u>Attributable excess healthcare utilization</u></b> .....	115
Supplementary Table 149 Excess number of healthcare encounters <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males according to different estimates of the attributable fraction (1997-2015).....	115
Supplementary Table 150 Excess number of clinician visits <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction .....	117
Supplementary Table 151 Excess number of hospital admissions <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction .....	118
Supplementary Table 152 Excess number of ER visits <sup>1,2</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction .....	119
Supplementary Table 153 Excess number of prescriptions <sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction .....	120
References .....	120

## Supplementary tables

Supplementary Table 1: **ICD-O-3 topography and morphology codes for HPV-related cancers of interest**

<b>Cancer</b>	<b>ICD-O-3 Topography</b>	<b>ICD-O-3 Morphology</b>
Penile	C60*	Squamous cell carcinoma (8050-8084, 8120-8131)
Anal	C21*	Squamous cell carcinoma (8050-8084, 8120-8131; exclude 8077/2)
Oropharyngeal	C01*, C02.4, C02.8, C09*, C10.2, C10.8, C10.9, C14*	Squamous cell carcinoma (8050-8084, 8120-8131)
Oral cavity	C00.3, C00.4, C00.5, C02.0, C02.1, C02.2, C02.3, C02.9, C03* - C06*	Squamous cell carcinoma (8050-8084, 8120-8131)

Supplementary Table 2: **Tariff codes used to identify male patients with anogenital warts in the medical claims [1]**

<b>Code</b>	<b>Description</b>
3372	Anus, condyloma, single or multiple, internal or external, destruction, in hospital
3433	Anus, condyloma, external, electrodesiccation, initial, per sitting
3434	Anus, condyloma, external, electrodesiccation, subsequent, per sitting
4120	Penis, penile skin lesion, including warts, local excision or fulguration, per sitting

Supplementary Table 3: **Identification of hospitalized patients with anogenital warts [1]**

<b>Date</b>	<b>ICD version</b>	<b>Criteria</b>	<b>Number of fields<sup>1</sup></b>
04/1994-03/2004	9	078.11 diagnosis OR (078.10 / 078.19 diagnosis AND related procedure)	16 diagnosis and 12 procedure
>03/2004	10	A630 diagnosis OR (B07 diagnosis AND related procedure)	25 diagnosis and 20 procedure

<sup>1</sup> All diagnostic and procedure fields were included.

Supplementary Table 4: **ICD-9-CM procedure codes used to assist in the identification of a male with anogenital warts** [1]

<b>Code</b>	<b>Description</b>
48.82	Excision of perirectal tissue
49.04	Other excision of perianal tissue
49.3	Local excision or destruction of other lesion or tissue of anus
58.3	Excision or destruction of lesion or tissue of urethra
61.3	Excision or destruction of lesion or tissue of scrotum
64.2	Local excision or destruction of lesion of penis

Supplementary Table 5: **ICD-10 procedure codes used to assist in the identification of a male with anogenital warts** [1]

<b>Code</b>	<b>Description</b>
1.NT.59.CA.GX	Destruction anus using per orifice approach and device NEC
1.PQ.59.LA.GX	Destruction urethra using open approach and device NEC
1.RY.87.LA	Excision, partial perineum

Supplementary Table 6: **Tariff codes for treatment of anogenital warts used to assist in the identification of a male with anogenital warts** [1]

<b>Code</b>	<b>Description</b>
0253	Excision & simple closure – single lesion, any location
0254	Excision & simple closure – each additional lesion to a maximum of four
0255	Excision & closure – multiple lesions, extensive
0397	Laser vaporization, other than face, one lesion
0398	Laser vaporization, other than face, two lesions
0399	Laser vaporization, other than face, three or more lesions
0401	Cautery (electro, chemo, or simple surgical excision, one lesion) elsewhere
0402	Warts & fibrocyanous tags - simple
0404	Cryocautery, etc., of benign lesion of skin, etc., second lesion
0405	Cryocautery, etc., of benign lesion of skin, etc., subsequent lesions (each)
0406	Cryocautery, etc., of benign lesion of skin, etc., complicated lesions
3300	Rectum, villous papilloma of rectum, extensive, local excision
3301	Rectum, unlisted or unusually complicated
3311	Rectum, proctosigmoidoscopy
3315	Rectum, proctosigmoidoscopy with removal of polyp or papilloma, single
3317	Rectum, proctosigmoidoscopy with removal of polyp or papilloma, multiple
3429	Anus, unlisted or unusually complicated
3994	Urethroscopy, therapeutic, polyps, urethral, excision of fulguration with or without urethroscopy
4000	Urethra, urethroscopy, diagnostic, initial or subsequent
4221	Scrotum, skin lesion, local excision
4229	Scrotum, unlisted or unusually complicated
8501	Office visits, regional, history and examination
8502	Office visits, complete or extensive re-examination for same illness
8507	Office visits, subsequent visit

Supplementary Table 7 **Fraction of HPV-related diseases attributable to the HPV types included in different HPV vaccines [2]**

<b>HPV-related disease</b>	<b>Bivalent<sup>1</sup></b>	<b>Quadrivalent<sup>2</sup></b>	<b>Nonavalent<sup>3</sup></b>
Anogenital warts	0%	90%	90%
Carcinoma <i>in situ</i> of the anus	79%	79%	83%
Carcinoma <i>in situ</i> of the oral cavity	22%	22%	26%
Carcinoma <i>in situ</i> of the oropharynx	63%	63%	68%
Carcinoma <i>in situ</i> of the penis	48%	48%	57%
Invasive cancer of the anus	79%	79%	83%
Invasive cancer of the oral cavity	22%	22%	26%
Invasive cancer of the oropharynx	63%	63%	68%
Invasive cancer of the penis	48%	48%	57%

<sup>1</sup> Includes HPV type 16 and 18; <sup>2</sup> Includes HPV-type 6, 11, 16, and 18; <sup>3</sup> Includes HPV-type 6, 11, 16, 18, 31, 33, 45, 52, and 58

Supplementary Table 8 **Overall fraction of HPV-related diseases attributable to any HPV type**

<b>HPV-related disease</b>	<b>Volesky et al. [3]</b>	<b>Saraiya et al. [2]</b>
Anogenital warts	100%	100%
Carcinoma <i>in situ</i> of the anus	88%	89%
Carcinoma <i>in situ</i> of the oral cavity	8%	33%
Carcinoma <i>in situ</i> of the oropharynx	60%	72%
Carcinoma <i>in situ</i> of the penis	39%	63%
Invasive cancer of the anus	88%	89%
Invasive cancer of the oral cavity	8%	33%
Invasive cancer of the oropharynx	60%	72%
Invasive cancer of the penis	39%	63%

### Incidence Rates

Supplementary Table 9 **Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by regional health authority of residence (1997 - 2016).**

Regional health authority of residence	Diseases					
	Anogenital warts	All CIS	CA anus	CA oral cavity	CA oropharynx	CA penis
Winnipeg	174 (170-177)	1.4 (1.0-1.7)	1.0 (0.7-1.3)	5.6 (5.0-6.3)	6.9 (6.2-7.7)	1.4 (1.0-1.7)
Interlake-Eastern	105 (98-111)	1.0 (0.4-1.6)	0.8 (0.2-1.3)	4.8 (3.4-6.1)	6.1 (4.6-7.7)	1.6 (0.8-2.4)
Northern	59 (53-65)	2.1 (0.4-3.8)	1.1 (0.0-2.5)	3.6 (1.5-5.6)	6.2 (3.5-9.0)	2.5 (0.7-4.3)
Southern	91 (86-96)	0.5 (0.1-0.9)	0.4 (0.0-0.7)	4.5 (3.2-5.7)	3.8 (2.7-4.9)	1.3 (0.6-1.9)
Prairie Mountain	113 (108-119)	0.5 (0.1-0.9)	0.6 (0.2-1.0)	4.0 (2.9-5.0)	5.3 (4.1-6.6)	2.9 (2.0-3.8)
Public Trustee/In CFS care	70 (41-98)	1.5 (0.0-4.4)	0.0 (0.0-0.0)	13.4 (3.8-23.1)	9.3 (0.0-19.8)	3.0 (0.0-7.2)
<b>Overall</b>	<b>141 (139-143)</b>	<b>1.1 (0.9-1.3)</b>	<b>0.8 (0.6-1.0)</b>	<b>5.1 (4.6-5.6)</b>	<b>6.2 (5.7-6.7)</b>	<b>1.7 (1.4-2.0)</b>

CA: Invasive cancer, CIS: Carcinoma *in situ*

Supplementary Table 10 **Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by Winnipeg region of residence (1997 - 2016).**

Winnipeg region of residence	Diseases					
	Anogenital warts	All CIS	CA anus	CA oral cavity	CA oropharynx	CA penis
Northern suburbs	154 (149-160)	1.2 (0.7-1.7)	0.7 (0.3-1.2)	4.3 (3.3-5.4)	6.6 (5.3-7.9)	1.0 (0.5-1.5)
Inner city	174 (166-181)	1.9 (0.9-3.0)	1.5 (0.7-2.4)	7.5 (5.4-9.5)	7.5 (5.6-9.5)	2.8 (1.5-4.1)
Southern suburbs	188 (183-192)	1.3 (0.9-1.8)	1.0 (0.6-1.4)	5.9 (5.0-6.9)	7.0 (6.0-8.0)	1.2 (0.8-1.6)
<b>Overall</b>	<b>174 (171-177)</b>	<b>1.4 (1.0-1.7)</b>	<b>1.0 (0.7-1.3)</b>	<b>5.6 (5.0-6.3)</b>	<b>7.0 (6.2-7.7)</b>	<b>1.4 (1.0-1.7)</b>

CA: Invasive cancer, CIS: Carcinoma *in situ*



Supplementary Table 11 **Age-standardized incidence rates (95% confidence interval) per 100,000 person-years of HPV-related diseases among Manitoba males by year of diagnosis.**

Year of diagnosis	Diseases					
	Anogenital warts	All CIS	CA anus	CA oral cavity	CA oropharynx	CA penis
1997	144 (134-154)	0.5 (0.0-1.2)	0.5 (0.0-1.2)	6.4 (3.7-9.0)	4.9 (2.6-7.1)	0.4 (0.0-1.1)
1998	121 (112-131)	0.7 (0.0-1.6)	0.8 (0.0-1.7)	5.8 (3.4-8.3)	4.6 (2.4-6.8)	1.4 (0.2-2.7)
1999	110 (101-119)	0.5 (0.0-1.1)	0.7 (0.0-1.5)	5.1 (2.8-7.4)	3.7 (1.8-5.6)	1.7 (0.4-3.0)
2000	117 (108-126)	1.2 (0.1-2.3)	0.6 (0.0-1.3)	5.2 (3.0-7.5)	5.1 (2.9-7.3)	1.6 (0.4-2.8)
2001	113 (104-122)	0.8 (0.0-1.7)	0.3 (0.0-0.8)	5.5 (3.2-7.8)	5.7 (3.4-8.1)	2.2 (0.7-3.6)
2002	131 (121-140)	2.1 (0.6-3.6)	0.7 (0.0-1.6)	5.3 (3.0-7.6)	5.9 (3.5-8.3)	1.3 (0.2-2.5)
2003	135 (125-144)	0.5 (0.0-1.2)	0.5 (0.0-1.2)	4.2 (2.2-6.3)	6.0 (3.6-8.4)	1.7 (0.4-3.0)
2004	141 (130-151)	2.3 (0.9-3.8)	1.0 (0.1-1.9)	4.5 (2.5-6.6)	6.1 (3.8-8.5)	1.2 (0.1-2.2)
2005	148 (138-158)	1.0 (0.0-2.0)	0.6 (0.0-1.3)	4.7 (2.6-6.8)	5.0 (2.9-7.1)	1.0 (0.0-2.0)
2006	143 (133-153)	0.7 (0.0-1.5)	0.7 (0.0-1.5)	5.3 (3.1-7.5)	6.0 (3.7-8.3)	0.8 (0.0-1.6)
2007	135 (125-145)	1.3 (0.3-2.4)	1.4 (0.3-2.5)	4.7 (2.7-6.8)	7.2 (4.7-9.8)	2.2 (0.8-3.7)
2008	152 (142-163)	0.5 (0.0-1.1)	1.2 (0.1-2.2)	5.2 (3.1-7.4)	6.4 (4.1-8.8)	2.7 (1.2-4.3)
2009	153 (143-163)	1.5 (0.4-2.6)	0.8 (0.0-1.6)	5.4 (3.3-7.6)	6.2 (3.9-8.5)	1.4 (0.3-2.5)
2010	163 (152-173)	1.1 (0.1-2.0)	0.9 (0.0-1.7)	6.5 (4.2-8.9)	6.7 (4.3-9.1)	0.5 (0.0-1.1)
2011	160 (150-171)	1.0 (0.1-1.9)	1.1 (0.1-2.0)	5.7 (3.5-7.8)	8.6 (6.0-11.2)	1.1 (0.1-2.1)
2012	158 (148-168)	0.6 (0.0-1.3)	0.4 (0.0-0.9)	5.5 (3.4-7.6)	5.5 (3.4-7.6)	1.1 (0.1-2.0)
2013	139 (129-148)	1.1 (0.2-2.0)	1.4 (0.4-2.4)	3.4 (1.8-5.1)	6.4 (4.2-8.6)	2.0 (0.8-3.2)
2014	150 (140-160)	1.3 (0.3-2.2)	1.2 (0.2-2.1)	3.4 (1.8-5.0)	6.4 (4.2-8.6)	3.0 (1.5-4.5)
2015	149 (140-159)	1.1 (0.2-2.0)	1.1 (0.2-2.0)	6.3 (4.1-8.4)	6.8 (4.6-9.0)	3.9 (2.2-5.6)
2016	144 (135-154)	2.0 (0.8-3.2)	0.4 (0.0-0.9)	4.1 (2.4-5.8)	7.8 (5.4-10.1)	1.7 (0.6-2.8)
<b>Overall</b>	<b>141 (139-143)</b>	<b>1.1 (0.9-1.3)</b>	<b>0.8 (0.6-1.0)</b>	<b>5.1 (4.6-5.6)</b>	<b>6.2 (5.7-6.7)</b>	<b>1.7 (1.4-2.0)</b>

CA: Invasive cancer, CIS: Carcinoma *in situ*

Supplementary Table 12 **Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by age group and regional health authority and Winnipeg region of residence (1997 - 2016).**

Region	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
Winnipeg	24 (21-28)	439 (427-451)	212 (205-218)	82 (76-87)	38 (33-42)	188 (185-192)
Northern suburbs	21 (16-28)	396 (377-416)	187 (177-198)	69 (60-78)	34 (27-42)	166 (160-172)
Inner city	27 (19-38)	397 (372-423)	220 (205-235)	101 (86-117)	43 (32-58)	199 (190-208)
Southern suburbs	25 (21-31)	486 (468-504)	226 (216-235)	84 (77-92)	38 (33-44)	200 (195-205)
Interlake-Eastern	15 (10-23)	277 (254-302)	122 (110-134)	44 (36-54)	25 (18-33)	102 (96-109)
Northern	15 (9-24)	140 (122-161)	64 (54-77)	33 (23-48)	23 (11-44)	65 (59-72)
Southern	14 (10-19)	249 (232-268)	103 (94-113)	33 (26-41)	23 (16-30)	96 (91-101)
Prairie Mountain	23 (17-30)	357 (335-380)	102 (92-112)	41 (34-49)	21 (15-27)	114 (108-119)
Public Trustee/In CFS care	64 (32-114)	226 (117-394)	35 (7-102)	13 (0-73)	34 (9-88)	61 (42-87)
Overall	21 (19-24)	367 (359-375)	167 (162-171)	63 (59-66)	31 (28-34)	149 (147-152)

**Incidence Rates by age and year of diagnosis**

Supplementary Table 13 **Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	19 (15-24)	22 (17-27)	20 (16-25)	23 (19-29)	21 (19-24)
18-30	314 (299-330)	370 (354-387)	411 (394-428)	370 (355-386)	367 (359-375)
31-50	150 (142-158)	166 (157-174)	172 (163-181)	180 (171-189)	167 (163-171)
51-64	49 (42-57)	55 (48-63)	70 (63-78)	71 (64-78)	63 (59-67)
≥65	24 (19-30)	30 (25-37)	32 (27-39)	35 (30-41)	31 (28-34)
<b>Overall</b>	<b>131 (127-136)</b>	<b>148 (143-152)</b>	<b>160 (155-165)</b>	<b>156 (152-161)</b>	<b>149 (147-152)</b>

Supplementary Table 14 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma *in situ* among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)
18-30	0.4 (0.0-1.4)	0.2 (0.0-1.1)	0.4 (0.0-1.3)	0.5 (0.1-1.4)	0.4 (0.2-0.7)
31-50	0.3 (0.1-1.0)	0.2 (0.0-0.8)	0.6 (0.2-1.4)	1.0 (0.5-2.0)	0.6 (0.3-0.9)
51-64	1.6 (0.6-3.5)	1.8 (0.8-3.5)	1.1 (0.4-2.5)	1.9 (0.9-3.3)	1.6 (1.1-2.3)
≥65	1.2 (0.3-3.1)	4.7 (2.7-7.7)	3.3 (1.7-5.8)	2.4 (1.1-4.3)	2.9 (2.1-3.9)
<b>Overall</b>	<b>0.6 (0.3-1.0)</b>	<b>1.1 (0.7-1.5)</b>	<b>0.9 (0.6-1.4)</b>	<b>1.2 (0.8-1.6)</b>	<b>0.9 (0.8-1.2)</b>

Supplementary Table 15 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)

18-30	0.4 (0.0-1.4)	0.4 (0.0-1.4)	0.2 (0.0-1.0)	0.3 (0.0-1.2)	0.3 (0.1-0.7)
31-50	7.0 (5.4-9.0)	5.5 (4.0-7.3)	4.8 (3.5-6.6)	5.7 (4.2-7.5)	5.8 (5.0-6.6)
51-64	22.5 (18.0-27.8)	21.5 (17.4-26.3)	31.1 (26.5-36.3)	26.8 (22.8-31.3)	25.9 (23.7-28.3)
≥65	30.1 (24.4-36.6)	34.6 (28.6-41.5)	38.7 (32.6-45.7)	38.0 (32.4-44.4)	35.6 (32.6-38.8)
<b>Overall</b>	<b>10.0 (8.8-11.3)</b>	<b>10.3 (9.1-11.6)</b>	<b>13.0 (11.7-14.4)</b>	<b>12.9 (11.6-14.3)</b>	<b>11.6 (11.0-12.3)</b>

Supplementary Table 16 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)
18-30	0.0 (0.0-0.7)	0.2 (0.0-1.1)	0.0 (0.0-0.7)	0.0 (0.0-0.6)	0.0 (0.0-0.3)
31-50	0.3 (0.1-1.0)	0.7 (0.3-1.5)	0.2 (0.0-0.9)	0.2 (0.0-0.8)	0.4 (0.2-0.6)
51-64	1.3 (0.4-3.1)	0.9 (0.2-2.3)	2.5 (1.3-4.2)	2.4 (1.3-4.0)	1.9 (1.3-2.6)
≥65	0.9 (0.2-2.7)	1.5 (0.5-3.5)	2.5 (1.1-4.7)	1.7 (0.7-3.4)	1.6 (1.1-2.5)
<b>Overall</b>	<b>0.4 (0.2-0.8)</b>	<b>0.6 (0.4-1.0)</b>	<b>0.9 (0.6-1.3)</b>	<b>0.8 (0.5-1.2)</b>	<b>0.7 (0.6-0.9)</b>

Supplementary Table 17 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)
18-30	0.0 (0.0-0.7)	0.2 (0.0-1.1)	0.2 (0.0-1.0)	0.2 (0.0-0.9)	0.1 (0.0-0.4)
31-50	2.9 (1.9-4.2)	1.6 (0.9-2.7)	1.3 (0.6-2.3)	2.3 (1.4-3.6)	2.0 (1.6-2.6)
51-64	9.8 (6.9-13.5)	9.2 (6.6-12.5)	11.1 (8.4-14.3)	6.6 (4.7-9.0)	9.0 (7.7-10.5)
≥65	14.6 (10.7-19.3)	13.0 (9.5-17.5)	15.1 (11.4-19.7)	13.5 (10.2-17.4)	14.0 (12.2-16.1)
<b>Overall</b>	<b>4.5 (3.7-5.4)</b>	<b>3.9 (3.2-4.8)</b>	<b>4.7 (3.9-5.6)</b>	<b>4.1 (3.4-4.9)</b>	<b>4.3 (3.9-4.7)</b>

Supplementary Table 18 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by age group and year of diagnosis.**

Age group	Year of diagnosis				
	1997-2001	2002-2006	2007-2011	2012-2016	Overall
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)

18-30	0.0 (0.0-0.7)	0.0 (0.0-0.7)	0.0 (0.0-0.7)	0.0 (0.0-0.6)	0.0 (0.0-0.2)
31-50	3.0 (1.9-4.4)	2.9 (1.9-4.3)	3.1 (2.0-4.5)	2.7 (1.7-4.0)	2.9 (2.4-3.5)
51-64	9.3 (6.5-12.9)	10.8 (7.9-14.3)	16.4 (13.1-20.3)	15.4 (12.4-18.9)	13.4 (11.8-15.2)
≥65	10.6 (7.4-14.8)	14.5 (10.7-19.2)	14.0 (10.4-18.4)	13.5 (10.2-17.4)	13.2 (11.4-15.2)
<b>Overall</b>	<b>3.9 (3.1-4.7)</b>	<b>4.8 (4.0-5.7)</b>	<b>6.1 (5.2-7.1)</b>	<b>6.0 (5.1-6.9)</b>	<b>5.2 (4.8-5.7)</b>

Supplementary Table 19 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by age group and year of diagnosis.**

<b>Age group</b>	<b>Year of diagnosis</b>				
	<b>1997-2001</b>	<b>2002-2006</b>	<b>2007-2011</b>	<b>2012-2016</b>	<b>Overall</b>
9-17	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.0 (0.0-1.0)	0.0 (0.0-1.0)	0.0 (0.0-0.2)
18-30	0.4 (0.0-1.4)	0.0 (0.0-0.7)	0.0 (0.0-0.7)	0.2 (0.0-0.9)	0.1 (0.0-0.4)
31-50	0.8 (0.3-1.7)	0.2 (0.0-0.8)	0.2 (0.0-0.9)	0.5 (0.1-1.2)	0.4 (0.2-0.7)
51-64	2.1 (0.9-4.2)	0.7 (0.1-2.0)	1.1 (0.4-2.5)	2.4 (1.3-4.0)	1.6 (1.1-2.3)
≥65	3.9 (2.1-6.7)	5.6 (3.4-8.8)	7.1 (4.7-10.5)	9.4 (6.7-12.9)	6.7 (5.5-8.2)
<b>Overall</b>	<b>1.2 (0.8-1.7)</b>	<b>0.9 (0.6-1.4)</b>	<b>1.3 (0.9-1.8)</b>	<b>2.1 (1.6-2.7)</b>	<b>1.4 (1.2-1.6)</b>

**Incidence Rates by birth year cohort and year of diagnosis**

Supplementary Table 20 **Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	25 (18-34)	25 (17-35)	20 (12-33)	12 (5-27)	22 (18-28)
1930-1939	38 (30-47)	39 (31-50)	37 (29-48)	22 (15-32)	35 (31-40)
1940-1949	59 (51-68)	55 (47-64)	48 (41-57)	45 (37-54)	52 (48-57)
1950-1959	106 (97-117)	84 (76-93)	80 (72-89)	65 (57-73)	84 (80-89)
1960-1969	226 (213-241)	174 (162-186)	123 (112-133)	110 (101-120)	158 (152-164)
1970-1979	332 (314-351)	342 (324-361)	274 (258-291)	180 (168-193)	280 (272-288)
1980-1989	40 (34-47)	253 (238-269)	439 (419-459)	357 (340-375)	276 (268-284)
1990-1999	15 (6-33)	5 (2-8)	61 (54-69)	248 (234-262)	123 (117-130)
<b>Overall</b>	<b>131 (127-136)</b>	<b>148 (143-152)</b>	<b>160 (155-165)</b>	<b>156 (152-161)</b>	<b>149 (147-152)</b>

Supplementary Table 21 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma *in situ* among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	1.9 (0.4-5.5)	4.9 (1.8-10.7)	2.4 (0.3-8.6)	2.1 (0.1-11.5)	2.9 (1.5-5.1)
1930-1939	1.4 (0.3-4.2)	4.8 (2.2-9.1)	4.4 (1.8-9.0)	3.1 (0.8-7.9)	3.3 (2.1-5.0)
1940-1949	1.0 (0.2-2.8)	1.3 (0.4-3.4)	1.4 (0.4-3.7)	1.9 (0.6-4.5)	1.4 (0.8-2.3)
1950-1959	0.5 (0.1-1.7)	0.7 (0.1-2.1)	1.4 (0.5-3.1)	2.2 (1.0-4.2)	1.2 (0.7-1.8)
1960-1969	0.2 (0.0-1.3)	0.2 (0.0-1.3)	0.5 (0.1-1.6)	0.9 (0.2-2.3)	0.5 (0.2-0.9)
1970-1979	0.5 (0.1-1.8)	0.3 (0.0-1.5)	0.5 (0.1-1.8)	0.5 (0.1-1.7)	0.4 (0.2-0.9)
1980-1989	0.0 (0.0-0.9)	0.2 (0.0-1.3)	0.5 (0.1-1.7)	1.5 (0.6-3.2)	0.6 (0.3-1.1)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.2 (0.0-1.2)	0.1 (0.0-0.5)
<b>Overall</b>	<b>0.6 (0.3-1.0)</b>	<b>1.1 (0.7-1.5)</b>	<b>0.9 (0.6-1.4)</b>	<b>1.2 (0.8-1.6)</b>	<b>0.9 (0.8-1.2)</b>



Supplementary Table 22 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	27.6 (20.0-37.0)	37.6 (27.6-50.2)	31.1 (20.3-45.5)	24.8 (12.8-43.3)	30.9 (25.8-36.8)
1930-1939	25.2 (18.9-32.9)	32.5 (24.9-41.8)	38.6 (29.6-49.5)	32.4 (23.3-43.7)	31.7 (27.6-36.2)
1940-1949	20.1 (15.4-25.7)	23.8 (18.6-30.0)	43.9 (36.5-52.3)	41.6 (34.1-50.2)	31.7 (28.5-35.1)
1950-1959	12.0 (9.0-15.7)	13.1 (9.9-17.1)	22.1 (17.8-27.1)	32.3 (27.0-38.4)	19.7 (17.6-21.9)
1960-1969	0.7 (0.1-2.0)	3.2 (1.8-5.4)	6.3 (4.2-9.1)	12.0 (9.0-15.6)	5.6 (4.5-6.8)
1970-1979	0.5 (0.1-1.8)	1.3 (0.4-3.0)	2.0 (0.9-4.0)	3.6 (2.0-5.9)	1.9 (1.3-2.7)
1980-1989	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.2 (0.0-1.3)	1.8 (0.8-3.5)	0.5 (0.2-1.0)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.2 (0.0-1.2)	0.1 (0.0-0.5)
<b>Overall</b>	<b>10.0 (8.8-11.3)</b>	<b>10.3 (9.1-11.6)</b>	<b>13.0 (11.7-14.4)</b>	<b>12.9 (11.6-14.3)</b>	<b>11.6 (11.0-12.3)</b>

Supplementary Table 23 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	0.6 (0.0-3.5)	3.3 (0.9-8.4)	1.2 (0.0-6.7)	0.0 (0.0-7.6)	1.4 (0.5-3.2)
1930-1939	1.9 (0.5-4.9)	0.5 (0.0-3.0)	3.7 (1.4-8.1)	2.3 (0.5-6.8)	2.0 (1.1-3.4)
1940-1949	0.6 (0.1-2.3)	1.0 (0.2-2.9)	2.5 (1.0-5.1)	1.6 (0.4-4.0)	1.4 (0.8-2.3)
1950-1959	0.7 (0.1-2.0)	0.5 (0.1-1.7)	1.9 (0.8-3.8)	3.0 (1.5-5.2)	1.5 (1.0-2.2)
1960-1969	0.0 (0.0-0.8)	0.9 (0.2-2.3)	0.2 (0.0-1.3)	0.7 (0.1-1.9)	0.5 (0.2-0.9)
1970-1979	0.0 (0.0-0.9)	0.5 (0.1-1.9)	0.3 (0.0-1.4)	0.0 (0.0-0.9)	0.2 (0.0-0.6)
1980-1989	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.2 (0.0-1.2)	0.1 (0.0-0.3)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.0 (0.0-0.8)	0.0 (0.0-0.3)
<b>Overall</b>	<b>0.4 (0.2-0.8)</b>	<b>0.6 (0.4-1.0)</b>	<b>0.9 (0.6-1.3)</b>	<b>0.8 (0.5-1.2)</b>	<b>0.7 (0.6-0.9)</b>

Supplementary Table 24 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	12.5 (7.7-19.3)	14.7 (8.7-23.3)	13.1 (6.6-23.5)	12.4 (4.6-27.0)	13.3 (10.0-17.3)
1930-1939	12.8 (8.4-18.7)	11.2 (6.9-17.1)	13.7 (8.6-20.8)	11.6 (6.5-19.1)	12.3 (9.9-15.3)
1940-1949	9.2 (6.2-13.3)	9.4 (6.2-13.5)	15.7 (11.4-21.1)	14.8 (10.4-20.3)	12.1 (10.2-14.3)
1950-1959	4.4 (2.6-6.8)	5.6 (3.6-8.4)	8.2 (5.7-11.4)	7.9 (5.4-11.2)	6.5 (5.3-7.8)
1960-1969	0.2 (0.0-1.3)	0.7 (0.1-2.0)	1.8 (0.8-3.6)	2.9 (1.5-4.9)	1.4 (0.9-2.1)
1970-1979	0.0 (0.0-0.9)	0.5 (0.1-1.9)	0.5 (0.1-1.8)	2.1 (1.0-4.1)	0.8 (0.4-1.4)
1980-1989	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.2 (0.0-1.3)	0.9 (0.2-2.2)	0.3 (0.1-0.7)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.0 (0.0-0.8)	0.0 (0.0-0.3)
<b>Overall</b>	<b>4.5 (3.7-5.4)</b>	<b>3.9 (3.2-4.8)</b>	<b>4.7 (3.9-5.6)</b>	<b>4.1 (3.4-4.9)</b>	<b>4.3 (3.9-4.7)</b>

Supplementary Table 25 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	13.2 (8.1-20.1)	11.5 (6.3-19.2)	9.6 (4.1-18.8)	4.1 (0.5-14.9)	10.9 (7.9-14.5)
1930-1939	7.6 (4.3-12.3)	17.6 (12.1-24.7)	13.1 (8.1-20.0)	6.2 (2.7-12.1)	11.3 (9.0-14.1)
1940-1949	8.6 (5.7-12.5)	12.4 (8.7-17.1)	22.5 (17.3-28.7)	17.1 (12.4-22.9)	14.9 (12.7-17.3)
1950-1959	5.3 (3.4-8.0)	6.6 (4.4-9.5)	11.3 (8.3-15.0)	18.8 (14.8-23.5)	10.3 (8.9-12.0)
1960-1969	0.5 (0.1-1.6)	1.4 (0.5-3.0)	4.1 (2.4-6.4)	7.5 (5.2-10.5)	3.4 (2.6-4.4)
1970-1979	0.0 (0.0-0.9)	0.3 (0.0-1.5)	1.3 (0.4-3.0)	1.2 (0.4-2.8)	0.7 (0.3-1.2)
1980-1989	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.4 (0.1-1.6)	0.1 (0.0-0.4)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.0 (0.0-0.8)	0.0 (0.0-0.3)
<b>Overall</b>	<b>3.9 (3.1-4.7)</b>	<b>4.8 (4.0-5.7)</b>	<b>6.1 (5.2-7.1)</b>	<b>6.0 (5.1-6.9)</b>	<b>5.2 (4.8-5.7)</b>

Supplementary Table 26 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by birth year and year of diagnosis.**

Birth year	Year of diagnosis				Overall
	1997-2001	2002-2006	2007-2011	2012-2016	
1920-1929	1.3 (0.2-4.5)	8.2 (3.9-15.0)	7.2 (2.6-15.6)	8.3 (2.3-21.2)	5.3 (3.3-8.0)
1930-1939	2.8 (1.0-6.2)	3.2 (1.2-7.0)	8.1 (4.3-13.9)	12.3 (7.0-20.0)	6.0 (4.3-8.1)
1940-1949	1.6 (0.5-3.7)	1.0 (0.2-2.9)	3.2 (1.5-6.1)	8.2 (5.0-12.5)	3.3 (2.3-4.5)
1950-1959	1.6 (0.6-3.3)	0.5 (0.1-1.7)	0.7 (0.1-2.1)	2.7 (1.4-4.9)	1.4 (0.9-2.1)
1960-1969	0.0 (0.0-0.8)	0.2 (0.0-1.3)	0.2 (0.0-1.3)	0.9 (0.2-2.3)	0.3 (0.1-0.7)
1970-1979	0.5 (0.1-1.8)	0.0 (0.0-1.0)	0.0 (0.0-0.9)	0.2 (0.0-1.3)	0.2 (0.0-0.6)
1980-1989	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.0 (0.0-0.9)	0.2 (0.0-1.2)	0.1 (0.0-0.3)
1990-1999	0.0 (0.0-9.3)	0.0 (0.0-1.5)	0.0 (0.0-0.9)	0.2 (0.0-1.2)	0.1 (0.0-0.5)
<b>Overall</b>	<b>1.2 (0.8-1.7)</b>	<b>0.9 (0.6-1.4)</b>	<b>1.3 (0.9-1.8)</b>	<b>2.1 (1.6-2.7)</b>	<b>1.4 (1.2-1.6)</b>

**Incidence Rates by birth year cohort and age**

Supplementary Table 27 **Crude incidence rates (95% confidence interval) per 100,000 person-years of anogenital warts among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	22 (18-28)	22 (18-28)
1930-1939	n/a	n/a	n/a	44 (34-57)	33 (28-38)	35 (31-40)
1940-1949	n/a	n/a	91 (69-119)	53 (48-59)	43 (37-51)	52 (48-57)
1950-1959	n/a	n/a	102 (95-110)	68 (63-74)	52 (21-107)	84 (80-89)
1960-1969	n/a	349 (304-399)	157 (151-164)	92 (79-108)	n/a	158 (152-164)
1970-1979	172 (69-355)	354 (340-368)	223 (214-233)	n/a	n/a	280 (272-288)
1980-1989	28 (23-33)	392 (380-404)	289 (263-316)	n/a	n/a	276 (268-284)
1990-1999	20 (17-23)	328 (310-347)	n/a	n/a	n/a	123 (117-130)
<b>Overall</b>	<b>21 (19-24)</b>	<b>367 (359-375)</b>	<b>167 (163-171)</b>	<b>63 (59-67)</b>	<b>31 (28-34)</b>	<b>149 (147-152)</b>

Supplementary Table 28 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related carcinoma *in situ* among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	2.9 (1.5-5.1)	2.9 (1.5-5.1)
1930-1939	n/a	n/a	n/a	2.9 (0.8-7.3)	3.5 (2.1-5.4)	3.3 (2.1-5.0)
1940-1949	n/a	n/a	0.0 (0.0-6.1)	1.1 (0.5-2.1)	2.3 (1.0-4.6)	1.4 (0.8-2.3)
1950-1959	n/a	n/a	0.4 (0.1-1.1)	1.9 (1.1-3.1)	0.0 (0.0-27.4)	1.2 (0.7-1.8)
1960-1969	n/a	0.0 (0.0-5.9)	0.4 (0.1-0.9)	1.2 (0.1-4.2)	n/a	0.5 (0.2-0.9)
1970-1979	0.0 (0.0-90.9)	0.3 (0.0-1.0)	0.6 (0.2-1.3)	n/a	n/a	0.4 (0.2-0.9)
1980-1989	0.0 (0.0-0.7)	0.5 (0.2-1.1)	3.1 (1.0-7.3)	n/a	n/a	0.6 (0.3-1.1)
1990-1999	0.0 (0.0-0.5)	0.3 (0.0-1.4)	n/a	n/a	n/a	0.1 (0.0-0.5)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.4 (0.2-0.7)</b>	<b>0.6 (0.3-0.9)</b>	<b>1.6 (1.1-2.3)</b>	<b>2.9 (2.1-3.9)</b>	<b>0.9 (0.8-1.2)</b>

Supplementary Table 29 **Crude incidence rates (95% confidence interval) per 100,000 person-years of all HPV-related invasive cancers among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	30.9 (25.8-36.8)	30.9 (25.8-36.8)
1930-1939	n/a	n/a	n/a	24.4 (16.9-34.1)	33.5 (28.9-38.7)	31.7 (27.6-36.2)
1940-1949	n/a	n/a	13.3 (5.7-26.2)	27.0 (23.4-31.0)	45.1 (38.2-52.8)	31.7 (28.5-35.1)
1950-1959	n/a	n/a	10.7 (8.6-13.3)	27.3 (23.9-31.0)	51.9 (20.9-107.0)	19.7 (17.6-21.9)
1960-1969	n/a	0.0 (0.0-5.9)	4.7 (3.7-5.9)	15.6 (10.3-22.7)	n/a	5.6 (4.5-6.8)
1970-1979	0.0 (0.0-90.9)	0.6 (0.2-1.5)	2.9 (1.9-4.3)	n/a	n/a	1.9 (1.3-2.7)
1980-1989	0.0 (0.0-0.7)	0.2 (0.0-0.7)	4.4 (1.8-9.0)	n/a	n/a	0.5 (0.2-1.0)
1990-1999	0.0 (0.0-0.5)	0.3 (0.0-1.4)	n/a	n/a	n/a	0.1 (0.0-0.5)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.3 (0.1-0.7)</b>	<b>5.8 (5.0-6.6)</b>	<b>25.9 (23.7-28.3)</b>	<b>35.6 (32.6-38.8)</b>	<b>11.6 (11.0-12.3)</b>

Supplementary Table 30 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the anus among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	1.4 (0.5-3.2)	1.4 (0.5-3.2)
1930-1939	n/a	n/a	n/a	2.2 (0.4-6.3)	2.0 (1.0-3.6)	2.0 (1.1-3.4)
1940-1949	n/a	n/a	0.0 (0.0-6.1)	1.3 (0.6-2.5)	1.8 (0.6-3.8)	1.4 (0.8-2.3)
1950-1959	n/a	n/a	0.5 (0.1-1.3)	2.4 (1.5-3.7)	0.0 (0.0-27.4)	1.5 (1.0-2.2)
1960-1969	n/a	0.0 (0.0-5.9)	0.4 (0.1-0.9)	1.2 (0.1-4.2)	n/a	0.5 (0.2-0.9)
1970-1979	0.0 (0.0-90.9)	0.1 (0.0-0.8)	0.2 (0.0-0.8)	n/a	n/a	0.2 (0.0-0.6)
1980-1989	0.0 (0.0-0.7)	0.0 (0.0-0.4)	0.6 (0.0-3.5)	n/a	n/a	0.1 (0.0-0.3)
1990-1999	0.0 (0.0-0.5)	0.0 (0.0-0.9)	n/a	n/a	n/a	0.0 (0.0-0.3)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.0 (0.0-0.3)</b>	<b>0.4 (0.2-0.6)</b>	<b>1.9 (1.3-2.6)</b>	<b>1.6 (1.1-2.5)</b>	<b>0.7 (0.6-0.9)</b>

Supplementary Table 31 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oral cavity among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	13.3 (10.0-17.3)	13.3 (10.0-17.3)
1930-1939	n/a	n/a	n/a	11.5 (6.6-18.6)	12.6 (9.8-15.9)	12.3 (9.9-15.3)
1940-1949	n/a	n/a	8.3 (2.7-19.4)	10.3 (8.1-12.9)	16.7 (12.6-21.6)	12.1 (10.2-14.3)
1950-1959	n/a	n/a	3.8 (2.6-5.4)	8.8 (6.9-11.0)	14.8 (1.8-53.6)	6.5 (5.3-7.8)
1960-1969	n/a	0.0 (0.0-5.9)	1.3 (0.8-2.0)	2.9 (0.9-6.7)	n/a	1.4 (0.9-2.1)
1970-1979	0.0 (0.0-90.9)	0.1 (0.0-0.8)	1.3 (0.7-2.3)	n/a	n/a	0.8 (0.4-1.4)
1980-1989	0.0 (0.0-0.7)	0.2 (0.0-0.7)	1.9 (0.4-5.5)	n/a	n/a	0.3 (0.1-0.7)
1990-1999	0.0 (0.0-0.5)	0.0 (0.0-0.9)	n/a	n/a	n/a	0.0 (0.0-0.3)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.1 (0.0-0.4)</b>	<b>2.0 (1.6-2.6)</b>	<b>9.0 (7.7-10.5)</b>	<b>14.0 (12.2-16.1)</b>	<b>4.3 (3.9-4.7)</b>

Supplementary Table 32 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the oropharynx among Manitoba males by birth year and age group.**

Birth year	Age group					Overall
	9-17	18-30	31-50	51-64	≥65	
1920-1929	n/a	n/a	n/a	n/a	10.9 (7.9-14.5)	10.9 (7.9-14.5)
1930-1939	n/a	n/a	n/a	8.6 (4.4-15.0)	12.0 (9.3-15.3)	11.3 (9.0-14.1)
1940-1949	n/a	n/a	5.0 (1.0-14.6)	13.8 (11.2-16.7)	19.0 (14.7-24.3)	14.9 (12.7-17.3)
1950-1959	n/a	n/a	5.3 (3.8-7.2)	14.5 (12.1-17.3)	37.1 (12.0-86.6)	10.3 (8.9-12.0)
1960-1969	n/a	0.0 (0.0-5.9)	2.7 (2.0-3.7)	10.4 (6.2-16.4)	n/a	3.4 (2.6-4.4)
1970-1979	0.0 (0.0-90.9)	0.0 (0.0-0.5)	1.2 (0.6-2.2)	n/a	n/a	0.7 (0.3-1.2)
1980-1989	0.0 (0.0-0.7)	0.0 (0.0-0.4)	1.2 (0.2-4.5)	n/a	n/a	0.1 (0.0-0.4)
1990-1999	0.0 (0.0-0.5)	0.0 (0.0-0.9)	n/a	n/a	n/a	0.0 (0.0-0.3)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.0 (0.0-0.2)</b>	<b>2.9 (2.4-3.5)</b>	<b>13.4 (11.8-15.2)</b>	<b>13.2 (11.4-15.2)</b>	<b>5.2 (4.8-5.7)</b>

Supplementary Table 33 **Crude incidence rates (95% confidence interval) per 100,000 person-years of invasive cancer of the penis among Manitoba males by birth year and age group.**

<b>Birth year</b>	<b>Age group</b>					<b>Overall</b>
	<b>9-17</b>	<b>18-30</b>	<b>31-50</b>	<b>51-64</b>	<b>≥65</b>	
1920-1929	n/a	n/a	n/a	n/a	5.3 (3.3-8.0)	5.3 (3.3-8.0)
1930-1939	n/a	n/a	n/a	2.2 (0.4-6.3)	6.9 (4.9-9.5)	6.0 (4.3-8.1)
1940-1949	n/a	n/a	0.0 (0.0-6.1)	1.6 (0.8-2.8)	7.6 (5.0-11.2)	3.3 (2.3-4.5)
1950-1959	n/a	n/a	1.1 (0.5-2.2)	1.6 (0.9-2.7)	0.0 (0.0-27.4)	1.4 (0.9-2.1)
1960-1969	n/a	0.0 (0.0-5.9)	0.3 (0.1-0.7)	1.2 (0.1-4.2)	n/a	0.3 (0.1-0.7)
1970-1979	0.0 (0.0-90.9)	0.3 (0.0-1.0)	0.1 (0.0-0.6)	n/a	n/a	0.2 (0.0-0.6)
1980-1989	0.0 (0.0-0.7)	0.0 (0.0-0.4)	0.6 (0.0-3.5)	n/a	n/a	0.1 (0.0-0.3)
1990-1999	0.0 (0.0-0.5)	0.3 (0.0-1.4)	n/a	n/a	n/a	0.1 (0.0-0.5)
<b>Overall</b>	<b>0.0 (0.0-0.2)</b>	<b>0.1 (0.0-0.4)</b>	<b>0.4 (0.2-0.7)</b>	<b>1.6 (1.1-2.3)</b>	<b>6.7 (5.5-8.2)</b>	<b>1.4 (1.2-1.6)</b>

### Costing

Supplementary Table 34 **Total net direct medical cost<sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males (1997-2015)**

HPV-related disease	Outpatient <sup>2</sup>	Hospital	Prescription drug	Total
Anogenital warts	\$6,132,360 (43%)	\$5,205,323 (37%)	\$2,826,318 (20%)	\$14,164,001 (100%)
All HPV-related carcinoma <i>in situ</i>	\$86,339 (63%)	\$11,247 (8%)	\$39,377 (29%)	\$136,963 (100%)
All HPV-related invasive cancers	\$7,041,975 (20%)	\$26,714,551 (77%)	\$1,148,023 (3%)	\$34,904,549 (100%)
Invasive cancer of the anus	\$503,078 (16%)	\$2,186,303 (70%)	\$451,911 (14%)	\$3,141,291 (100%)
Invasive cancer of the oral cavity	\$3,419,404 (20%)	\$13,703,381 (78%)	\$364,917 (2%)	\$17,487,701 (100%)
Invasive cancer of the oropharynx	\$2,744,239 (23%)	\$9,080,347 (76%)	\$175,920 (1%)	\$12,000,506 (100%)
Invasive cancer of the penis	\$375,255 (16%)	\$1,744,521 (77%)	\$155,275 (7%)	\$2,275,051 (100%)
<b>Total</b>	<b>\$13,260,674 (27%)</b>	<b>\$31,931,122 (65%)</b>	<b>\$4,013,717 (8%)</b>	<b>\$49,205,513 (100%)</b>

<sup>1</sup> The periods for which costs were added were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Outpatient cost includes diagnostic and therapeutic procedures.

Supplementary Table 35 **Total net direct medical cost<sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

HPV-related disease	Age (years)					Total
	9 - 17	18 - 30	31 - 50	51 - 64	≥65	
Anogenital warts	\$306,100 (2%)	\$4,032,794 (28%)	\$6,768,276 (48%)	\$2,179,081 (15%)	\$877,750 (6%)	\$14,164,001 (100%)
All HPV-related carcinoma <i>in situ</i>		\$772 (1%)	\$10,651 (8%)	\$65,867 (48%)	\$59,674 (44%)	\$136,963 (100%)
All HPV-related invasive cancers		\$189,539 (1%)	\$6,013,725 (17%)	\$16,369,060 (47%)	\$12,332,225 (35%)	\$34,904,549 (100%)
Invasive cancer of the anus		\$43,629 (1%)	\$754,659 (24%)	\$1,369,170 (44%)	\$973,833 (31%)	\$3,141,291 (100%)
Invasive cancer of the oral cavity		\$88,918 (1%)	\$2,571,585 (15%)	\$7,627,090 (44%)	\$7,200,108 (41%)	\$17,487,701 (100%)
Invasive cancer of the oropharynx			\$2,433,804 (20%)	\$6,968,059 (58%)	\$2,598,643 (22%)	\$12,000,506 (100%)
Invasive cancer of the penis		\$56,992 (3%)	\$253,677 (11%)	\$404,741 (18%)	\$1,559,642 (69%)	\$2,275,051 (100%)
<b>Total</b>	<b>\$306,100 (1%)</b>	<b>\$4,223,105 (9%)</b>	<b>\$12,792,651 (26%)</b>	<b>\$18,614,008 (38%)</b>	<b>\$13,269,649 (27%)</b>	<b>\$49,205,513 (100%)</b>



<sup>1</sup> The periods for which costs were added were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 36 **Total net direct medical cost<sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority of residence (1997-2015)**

HPV-related disease	Regional Health Authority of Residence						Total
	Winnipeg	Interlake-Eastern	Northern	Southern	Prairie Mountain	Public Trustee/In CFS care	
Anogenital warts	\$10,291,905 (73%)	\$1,110,305 (8%)	\$510,831 (4%)	\$843,248 (6%)	\$1,273,611 (9%)	\$134,102 (1%)	\$14,164,001 (100%)
All HPV-related carcinoma <i>in situ</i>	\$98,495 (72%)	\$4,050 (3%)	\$14,074 (10%)	\$8,135 (6%)	\$12,098 (9%)	\$110 (0%)	\$136,963 (100%)
All HPV-related invasive cancers	\$19,359,700 (55%)	\$3,386,209 (10%)	\$1,453,136 (4%)	\$4,295,468 (12%)	\$6,208,382 (18%)	\$201,653 (1%)	\$34,904,549 (100%)
Invasive cancer of the anus	\$2,057,537 (65%)	\$334,783 (11%)	\$115,968 (4%)	\$214,838 (7%)	\$418,166 (13%)		\$3,141,291 (100%)
Invasive cancer of the oral cavity	\$9,932,019 (57%)	\$1,379,913 (8%)	\$745,366 (4%)	\$2,832,054 (16%)	\$2,483,375 (14%)	\$114,975 (1%)	\$17,487,701 (100%)
Invasive cancer of the oropharynx	\$6,544,309 (55%)	\$1,320,713 (11%)	\$512,859 (4%)	\$940,596 (8%)	\$2,611,438 (22%)	\$70,591 (1%)	\$12,000,506 (100%)
Invasive cancer of the penis	\$825,835 (36%)	\$350,801 (15%)	\$78,943 (3%)	\$307,980 (14%)	\$695,404 (31%)	\$16,088 (1%)	\$2,275,051 (100%)
<b>Total</b>	<b>\$29,750,100 (60%)</b>	<b>\$4,500,564 (9%)</b>	<b>\$1,978,042 (4%)</b>	<b>\$5,146,850 (10%)</b>	<b>\$7,494,091 (15%)</b>	<b>\$335,866 (1%)</b>	<b>\$49,205,513 (100%)</b>

<sup>1</sup> The periods for which costs were added were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 37 **Total net direct medical cost<sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by Winnipeg region of residence (1997-2015)**

HPV-related disease	Winnipeg Region of Residence			
	Northern suburbs	Inner city	Southern suburbs	Total
Anogenital warts	\$3,113,466 (30%)	\$3,479,377 (34%)	\$3,695,021 (36%)	\$10,287,864 (100%)
All HPV-related carcinoma <i>in situ</i>	\$26,723 (27%)	\$15,928 (16%)	\$55,844 (57%)	\$98,495 (100%)
All HPV-related invasive cancers	\$4,923,590 (25%)	\$5,167,484 (27%)	\$9,268,626 (48%)	\$19,359,700 (100%)

Invasive cancer of the anus	\$248,425 (12%)	\$1,004,216 (49%)	\$804,896 (39%)	\$2,057,537 (100%)
Invasive cancer of the oral cavity	\$1,961,605 (20%)	\$2,925,407 (29%)	\$5,045,007 (51%)	\$9,932,019 (100%)
Invasive cancer of the oropharynx	\$2,439,652 (37%)	\$936,449 (14%)	\$3,168,207 (48%)	\$6,544,309 (100%)
Invasive cancer of the penis	\$273,907 (33%)	\$301,412 (36%)	\$250,516 (30%)	\$825,835 (100%)
<b>Total</b>	<b>\$8,063,779 (27%)</b>	<b>\$8,662,790 (29%)</b>	<b>\$13,019,491 (44%)</b>	<b>\$29,746,060 (100%)</b>

<sup>1</sup> The periods for which costs were added were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 38 **Total net direct medical cost<sup>1</sup> of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

HPV-related disease	Year of diagnosis																			
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	Total
Anogenital warts	\$458,210 (3%)	\$651,989 (5%)	\$384,438 (3%)	\$745,979 (5%)	\$436,459 (3%)	\$223,102 (2%)	\$1,458,77 9 (10%)	\$702,599 (5%)	\$932,401 (7%)	\$175,078 (1%)	\$693,234 (5%)	\$1,096,98 9 (8%)	\$688,491 (5%)	\$582,797 (4%)	\$1,225,56 4 (9%)	\$995,934 (7%)	\$618,053 (4%)	\$928,885 (7%)	\$1,165,01 8 (8%)	\$14,164,00 1 (100%)
All HPV-related carcinoma <i>in situ</i>	\$5,939 (4%)	\$11,768 (9%)	\$220 (0%)	\$11,988 (9%)	\$6,049 (4%)	\$8,466 (6%)	\$5,939 (4%)	\$17,573 (13%)	\$11,878 (9%)	\$6,049 (4%)	\$15,157 (11%)	\$220 (0%)	\$661 (0%)	\$4,282 (3%)	\$3,720 (3%)	\$331 (0%)	\$6,380 (5%)	\$6,490 (5%)	\$13,854 (10%)	\$136,963 (100%)
All HPV-related invasive cancers	\$1,231,22 8 (4%)	\$1,363,43 8 (4%)	\$1,500,22 3 (4%)	\$1,386,81 5 (4%)	\$2,664,82 8 (8%)	\$1,472,79 3 (4%)	\$999,002 (3%)	\$2,010,31 7 (6%)	\$1,731,73 5 (5%)	\$1,452,53 6 (4%)	\$2,421,90 7 (7%)	\$2,555,43 2 (7%)	\$2,006,73 2 (6%)	\$2,495,59 5 (7%)	\$2,213,88 1 (6%)	\$1,967,29 0 (6%)	\$1,619,44 1 (5%)	\$1,840,82 4 (5%)	\$1,970,53 5 (6%)	\$34,904,54 9 (100%)
Invasive cancer of the anus	\$66,977 (2%)	\$57,913 (2%)	\$231,475 (7%)	\$76,896 (2%)	\$43,629 (1%)	\$144,177 (5%)	\$67,705 (2%)	\$275,674 (9%)	\$170,611 (5%)	\$50,663 (2%)	\$408,308 (13%)	\$387,996 (12%)	\$254,276 (8%)	\$134,525 (4%)	\$53,809 (2%)	\$65,742 (2%)	\$444,210 (14%)	\$87,628 (3%)	\$119,077 (4%)	\$3,141,291 (100%)
Invasive cancer of the oral cavity	\$615,422 (4%)	\$625,013 (4%)	\$647,398 (4%)	\$443,167 (3%)	\$769,585 (4%)	\$614,283 (4%)	\$515,044 (3%)	\$1,328,59 1 (8%)	\$1,033,29 2 (6%)	\$915,372 (5%)	\$1,045,90 9 (6%)	\$1,727,16 8 (10%)	\$783,459 (4%)	\$1,727,41 8 (10%)	\$1,252,04 7 (7%)	\$1,200,01 1 (7%)	\$627,875 (4%)	\$643,446 (4%)	\$973,200 (6%)	\$17,487,70 1 (100%)
Invasive cancer of the oropharynx	\$328,640 (3%)	\$577,678 (5%)	\$506,862 (4%)	\$815,650 (7%)	\$1,757,93 5 (15%)	\$519,996 (4%)	\$334,081 (3%)	\$359,525 (3%)	\$487,759 (4%)	\$473,744 (4%)	\$855,394 (7%)	\$382,519 (3%)	\$861,457 (7%)	\$646,991 (5%)	\$823,213 (7%)	\$632,060 (5%)	\$475,021 (4%)	\$574,258 (5%)	\$587,723 (5%)	\$12,000,50 6 (100%)
Invasive cancer of the penis	\$220,189 (10%)	\$102,834 (5%)	\$114,488 (5%)	\$51,101 (2%)	\$93,679 (4%)	\$194,337 (9%)	\$82,173 (4%)	\$46,526 (2%)	\$40,073 (2%)	\$12,758 (1%)	\$112,296 (5%)	\$57,749 (3%)	\$107,540 (5%)	\$-13,338 (-1%)	\$84,811 (4%)	\$69,476 (3%)	\$72,334 (3%)	\$535,492 (24%)	\$290,535 (13%)	\$2,275,051 (100%)
<b>Total</b>	<b>\$1,695,377 (3%)</b>	<b>\$2,027,19 5 (4%)</b>	<b>\$1,884,88 2 (4%)</b>	<b>\$2,144,78 2 (4%)</b>	<b>\$3,107,336 (6%)</b>	<b>\$1,704,361 (3%)</b>	<b>\$2,463,72 0 (5%)</b>	<b>\$2,730,48 9 (6%)</b>	<b>\$2,676,01 4 (5%)</b>	<b>\$1,633,664 (3%)</b>	<b>\$3,130,29 7 (6%)</b>	<b>\$3,652,641 (7%)</b>	<b>\$2,695,88 5 (5%)</b>	<b>\$3,082,67 5 (6%)</b>	<b>\$3,443,165 (7%)</b>	<b>\$2,963,55 5 (6%)</b>	<b>\$2,243,87 3 (5%)</b>	<b>\$2,776,199 (6%)</b>	<b>\$3,149,40 6 (6%)</b>	<b>\$49,205,51 3 (100%)</b>

<sup>1</sup> The periods for which costs were added were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer



Supplementary Table 39 **Average of net direct medical cost of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by successive 90-day periods before and after diagnosis (1997-2015)**

<b>HPV-related disease</b>	<b>-360 to -271 days</b>	<b>-270 to -181 days</b>	<b>-180 to -91 days</b>	<b>-90 to -1 days</b>	<b>0 to 90 days</b>	<b>91 to 180 days</b>	<b>181 to 270 days</b>	<b>271 to 360 days</b>	<b>361 to 450 days</b>	<b>451 to 540 days</b>	<b>541 to 630 days</b>	<b>631 to 720 days</b>	<b>721 to 810 days</b>	<b>811 to 900 days</b>	<b>901 to 990 days</b>	<b>991 to 1080 days</b>
Anogenital warts	\$73	\$114	\$73	\$117	\$521	\$118	\$138	\$181	\$151	\$75	\$261	\$131	\$133	\$119	\$105	\$79
All HPV-related carcinoma <i>in situ</i>	\$-199	\$458	\$-207	\$2,221	\$1,303	\$322	\$-171	\$65	\$29	\$503	\$-77	\$1,266	\$2,700	\$608	\$-383	\$92
All HPV-related invasive cancers	\$216	\$118	\$-12	\$537	\$15,241	\$2,784	\$4,383	\$2,305	\$1,826	\$1,580	\$1,540	\$263	\$586	\$828	\$1,220	\$1,239
Invasive cancer of the anus	\$634	\$979	\$1,331	\$3,830	\$10,731	\$5,053	\$3,595	\$7,544	\$6,828	\$2,313	\$1,541	\$709	\$2,319	\$886	\$2,468	\$664
Invasive cancer of the oral cavity	\$560	\$251	\$191	\$874	\$25,338	\$3,196	\$3,925	\$2,683	\$2,077	\$1,316	\$1,054	\$119	\$265	\$1,828	\$961	\$46
Invasive cancer of the oropharynx	\$29	\$-19	\$-178	\$-307	\$9,886	\$2,228	\$5,732	\$1,493	\$1,219	\$1,282	\$1,821	\$448	\$515	\$125	\$727	\$567
Invasive cancer of the penis	\$-393	\$-260	\$-765	\$842	\$6,048	\$2,337	\$1,200	\$1,303	\$577	\$3,125	\$2,019	\$-225	\$915	\$289	\$3,200	\$7,830

Supplementary Table 40 **Median of net direct medical cost of HPV-related diseases (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by successive 90-day periods before and after diagnosis (1997-2015)**

<b>HPV-related disease</b>	<b>-360 to -271 days</b>	<b>-270 to -181 days</b>	<b>-180 to -91 days</b>	<b>-90 to -1 days</b>	<b>0 to 90 days</b>	<b>91 to 180 days</b>	<b>181 to 270 days</b>	<b>271 to 360 days</b>	<b>361 to 450 days</b>	<b>451 to 540 days</b>	<b>541 to 630 days</b>	<b>631 to 720 days</b>	<b>721 to 810 days</b>	<b>811 to 900 days</b>	<b>901 to 990 days</b>	<b>991 to 1080 days</b>
Anogenital warts	\$0	\$0	\$0	\$17	\$168	\$1	\$0	\$0	\$0	\$0	\$0	\$-1	\$-0	\$-1	\$0	\$0
All HPV-related carcinoma <i>in situ</i>	\$-45	\$0	\$-8	\$160	\$843	\$49	\$3	\$36	\$34	\$-6	\$-11	\$40	\$0	\$11	\$-8	\$0
All HPV-related invasive cancers	\$-34	\$-37	\$-34	\$219	\$6,355	\$401	\$211	\$100	\$87	\$47	\$0	\$0	\$0	\$0	\$0	\$0
Invasive cancer of the anus	\$49	\$-3	\$116	\$507	\$4,540	\$1,616	\$690	\$687	\$702	\$175	\$110	\$124	\$153	\$1	\$0	\$0
Invasive cancer of the oral cavity	\$-16	\$-23	\$-30	\$116	\$13,197	\$249	\$220	\$84	\$79	\$0	\$0	\$0	\$0	\$0	\$0	\$-5
Invasive cancer of the oropharynx	\$-45	\$-44	\$-40	\$266	\$5,104	\$474	\$204	\$88	\$73	\$64	\$0	\$0	\$0	\$0	\$0	\$0
Invasive cancer of the penis	\$-75	\$-55	\$-39	\$273	\$3,177	\$164	\$28	\$46	\$29	\$86	\$18	\$0	\$0	\$0	\$0	\$0

### Net cost by age

Supplementary Table 41 **Distribution of net direct medical cost<sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
9 - 17	\$1,004	\$5,558	\$305	\$28 - \$926
18 - 30	\$527	\$5,762	\$237	\$-3 - \$707
31 - 50	\$1,254	\$14,053	\$266	\$-175 - \$1,049
51 - 64	\$1,983	\$13,999	\$465	\$-646 - \$2,384
≥65	\$2,421	\$23,561	\$789	\$-1,269 - \$3,807
<b>Overall</b>	<b>\$958</b>	<b>\$10,883</b>	<b>\$256</b>	<b>\$-86 - \$941</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 42 **Distribution of net direct medical cost<sup>1</sup> of HPV-related carcinoma *in situ* (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	\$-804	\$5,429	\$439	\$361 - \$2,511
31 - 50	\$4,098	\$4,721	\$1,421	\$724 - \$8,038
51 - 64	\$2,408	\$3,563	\$2,042	\$559 - \$4,464
≥65	\$-348	\$18,221	\$1,025	\$-584 - \$4,641
<b>Overall</b>	<b>\$1,466</b>	<b>\$11,483</b>	<b>\$1,253</b>	<b>\$-45 - \$4,638</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 43 **Distribution of net direct medical cost<sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	\$29,182	\$18,455	\$27,283	\$25,192 - \$32,891
31 - 50	\$32,275	\$46,358	\$18,343	\$6,226 - \$44,239
51 - 64	\$34,883	\$89,325	\$16,538	\$5,357 - \$44,567
≥65	\$24,703	\$61,976	\$14,644	\$620 - \$39,968



---

<b>Overall</b>	<b>\$30,382</b>	<b>\$72,834</b>	<b>\$16,411</b>	<b>\$4,527 - \$43,189</b>
----------------	-----------------	-----------------	-----------------	---------------------------

---

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 44 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	\$59,252	\$53,357	\$41,240	\$13,041 - \$98,003
51 - 64	\$40,060	\$48,646	\$23,212	\$5,869 - \$62,087
≥65	\$39,966	\$69,811	\$21,659	\$11,627 - \$72,841
<b>Overall</b>	<b>\$43,629</b>	<b>\$56,467</b>	<b>\$23,712</b>	<b>\$10,213 - \$72,533</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 45 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	\$44,459	\$16,360	\$44,459	\$32,891 - \$56,028
31 - 50	\$38,115	\$47,299	\$23,903	\$5,194 - \$54,841
51 - 64	\$45,489	\$74,075	\$30,826	\$9,869 - \$59,381
≥65	\$37,076	\$69,133	\$24,857	\$2,546 - \$54,060
<b>Overall</b>	<b>\$40,669</b>	<b>\$67,962</b>	<b>\$27,175</b>	<b>\$7,307 - \$57,202</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 46 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	\$26,622	\$45,871	\$17,320	\$6,835 - \$29,638
51 - 64	\$29,455	\$106,293	\$12,868	\$4,589 - \$29,543
≥65	\$12,270	\$60,209	\$9,168	\$-4,552 - \$31,184
<b>Overall</b>	<b>\$23,530</b>	<b>\$84,366</b>	<b>\$12,551</b>	<b>\$3,683 - \$29,873</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 47 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by age group (1997-2015)**

<b>Age (years)</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
18 - 30	\$18,997	\$12,584	\$25,192	\$4,517 - \$27,283
31 - 50	\$18,246	\$24,334	\$6,893	\$1,308 - \$21,636
51 - 64	\$13,031	\$26,133	\$7,640	\$4,537 - \$17,639
≥65	\$17,278	\$37,488	\$9,852	\$1,127 - \$24,807
<b>Overall</b>	<b>\$16,486</b>	<b>\$33,336</b>	<b>\$9,417</b>	<b>\$2,806 - \$21,572</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

**Net cost by regional health authority and Winnipeg region of residence**

Supplementary Table 48 **Distribution of net direct medical cost<sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$976	\$12,207	\$251	\$-94 - \$918
Northern suburbs	\$1,006	\$10,467	\$254	\$-83 - \$927
Inner city	\$1,796	\$20,557	\$248	\$-157 - \$1,074
Southern suburbs	\$670	\$8,629	\$251	\$-90 - \$864
Interlake-Eastern	\$1,086	\$6,737	\$273	\$-62 - \$1,107
Northern	\$1,373	\$7,996	\$277	\$-44 - \$1,129
Southern	\$635	\$4,786	\$276	\$-27 - \$884
Prairie Mountain	\$852	\$6,604	\$251	\$-81 - \$929
Public Trustee/In CFS care	\$5,047	\$16,260	\$127	\$-904 - \$1,141
<b>Overall</b>	<b>\$958</b>	<b>\$10,883</b>	<b>\$256</b>	<b>\$-86 - \$941</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 49 **Distribution of net direct medical cost<sup>1</sup> of HPV-related carcinoma *in situ* (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$3,345	\$7,490	\$1,843	\$404 - \$4,881
Northern suburbs	\$4,849	\$7,587	\$1,989	\$697 - \$5,260
Inner city	\$1,747	\$7,996	\$626	\$-3,466 - \$3,922
Southern suburbs	\$3,125	\$7,327	\$2,097	\$310 - \$4,495
Interlake-Eastern	\$-1,909	\$14,044	\$398	\$-351 - \$4,003
Northern	\$3,840	\$5,604	\$1,659	\$361 - \$4,296
Southern	\$-24	\$2,916	\$-584	\$-2,620 - \$3,131
Prairie Mountain	\$-11,468	\$31,921	\$957	\$-29,690 - \$6,754
Public Trustee/In CFS care	S	S	S	S
<b>Overall</b>	<b>\$1,466</b>	<b>\$11,483</b>	<b>\$1,253</b>	<b>\$-45 - \$4,638</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively; S = Suppressed

Supplementary Table 50 **Distribution of net direct medical cost<sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$27,698	\$55,513	\$16,538	\$4,299 - \$43,078
Northern suburbs	\$25,213	\$44,383	\$16,699	\$4,273 - \$33,003
Inner city	\$38,559	\$83,948	\$29,913	\$9,944 - \$65,232
Southern suburbs	\$24,687	\$45,324	\$12,820	\$3,576 - \$40,018
Interlake-Eastern	\$26,191	\$42,774	\$15,460	\$5,136 - \$32,411
Northern	\$32,670	\$45,228	\$20,044	\$5,357 - \$47,807
Southern	\$43,908	\$96,860	\$29,986	\$7,374 - \$56,805
Prairie Mountain	\$38,688	\$128,945	\$12,361	\$4,340 - \$42,871
Public Trustee/In CFS care	\$1,294	\$36,797	\$-3,688	\$-28,523 - \$12,533
<b>Overall</b>	<b>\$30,382</b>	<b>\$72,834</b>	<b>\$16,411</b>	<b>\$4,527 - \$43,189</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 51 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$41,921	\$56,560	\$25,363	\$10,844 - \$69,693
Northern suburbs	\$22,584	\$37,865	\$13,037	\$3,887 - \$24,076
Inner city	\$71,730	\$47,536	\$58,765	\$33,308 - \$116,772
Southern suburbs	\$32,620	\$63,616	\$22,355	\$3,906 - \$49,172
Interlake-Eastern	\$41,593	\$59,313	\$11,136	\$8,731 - \$79,233
Northern	\$36,169	\$32,488	\$36,169	\$13,197 - \$59,142
Southern	\$57,070	\$56,885	\$70,718	\$-5,398 - \$105,889
Prairie Mountain	\$57,456	\$76,342	\$21,207	\$10,210 - \$74,348
<b>Overall</b>	<b>\$43,629</b>	<b>\$56,467</b>	<b>\$23,712</b>	<b>\$10,213 - \$72,533</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 52 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$37,102	\$53,830	\$26,064	\$6,274 - \$54,814
Northern suburbs	\$26,824	\$38,840	\$22,158	\$6,658 - \$35,040
Inner city	\$58,042	\$76,895	\$43,695	\$15,391 - \$67,897
Southern suburbs	\$33,960	\$47,170	\$18,397	\$4,555 - \$54,060
Interlake-Eastern	\$27,402	\$38,354	\$21,092	\$5,136 - \$34,934
Northern	\$54,207	\$61,381	\$35,557	\$17,066 - \$61,977
Southern	\$70,138	\$120,235	\$45,770	\$30,936 - \$73,998
Prairie Mountain	\$49,445	\$95,581	\$17,924	\$8,027 - \$67,908
Public Trustee/In CFS care	\$-1,407	\$44,599	\$-5,290	\$-28,523 - \$-3,688
<b>Overall</b>	<b>\$40,669</b>	<b>\$67,962</b>	<b>\$27,175</b>	<b>\$7,307 - \$57,202</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 53 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$20,073	\$58,667	\$12,868	\$3,683 - \$29,758
Northern suburbs	\$25,734	\$51,148	\$14,052	\$3,786 - \$29,543
Inner city	\$16,055	\$100,981	\$18,937	\$3,053 - \$55,912
Southern suburbs	\$18,367	\$40,836	\$10,006	\$3,457 - \$26,863
Interlake-Eastern	\$23,128	\$45,119	\$13,799	\$4,090 - \$28,172
Northern	\$23,263	\$29,282	\$14,598	\$2,258 - \$38,485
Southern	\$21,305	\$81,186	\$11,409	\$-1,648 - \$32,010
Prairie Mountain	\$43,945	\$185,728	\$11,752	\$4,604 - \$31,184
<b>Overall</b>	<b>\$23,530</b>	<b>\$84,366</b>	<b>\$12,551</b>	<b>\$3,683 - \$29,873</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 54 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015)**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	\$13,220	\$28,028	\$9,994	\$2,864 - \$20,996
Northern suburbs	\$17,210	\$29,165	\$16,672	\$2,864 - \$32,932
Inner city	\$19,174	\$22,974	\$12,495	\$4,537 - \$20,996
Southern suburbs	\$6,891	\$30,058	\$7,359	\$-2,286 - \$16,718
Interlake-Eastern	\$26,486	\$38,005	\$12,239	\$5,782 - \$23,217
Northern	\$3,250	\$23,723	\$9,801	\$-12,874 - \$19,373
Southern	\$25,001	\$30,176	\$16,264	\$1,127 - \$66,345
Prairie Mountain	\$16,999	\$40,373	\$9,048	\$-726 - \$21,572
Public Trustee/In CFS care	\$8,044	\$6,349	\$8,044	\$3,555 - \$12,533
<b>Overall</b>	<b>\$16,486</b>	<b>\$33,336</b>	<b>\$9,417</b>	<b>\$2,806 - \$21,572</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

**Net cost by year of diagnosis**

Supplementary Table 55 **Distribution of net direct medical cost<sup>1</sup> of anogenital warts (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$588	\$10,700	\$232	\$-21 - \$1,052
1998	\$1,005	\$4,622	\$205	\$-88 - \$1,160
1999	\$653	\$4,085	\$173	\$-100 - \$797
2000	\$1,200	\$17,041	\$238	\$-61 - \$1,019
2001	\$728	\$5,503	\$197	\$-94 - \$732
2002	\$312	\$4,756	\$176	\$-138 - \$695
2003	\$2,044	\$26,449	\$202	\$-105 - \$759
2004	\$928	\$7,921	\$264	\$-28 - \$878
2005	\$1,163	\$17,280	\$203	\$-112 - \$702
2006	\$217	\$7,553	\$183	\$-169 - \$660
2007	\$948	\$8,499	\$234	\$-93 - \$821
2008	\$1,329	\$9,361	\$242	\$-137 - \$835
2009	\$817	\$4,946	\$278	\$-85 - \$918
2010	\$633	\$4,565	\$342	\$-88 - \$1,052
2011	\$1,338	\$13,543	\$345	\$-11 - \$1,011
2012	\$1,067	\$6,414	\$315	\$-104 - \$975
2013	\$743	\$8,297	\$347	\$-75 - \$1,085
2014	\$1,025	\$8,102	\$391	\$-30 - \$1,196
2015	\$1,292	\$10,625	\$327	\$-89 - \$1,258
<b>Overall</b>	<b>\$958</b>	<b>\$10,883</b>	<b>\$256</b>	<b>\$-86 - \$941</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 56 **Distribution of net direct medical cost<sup>1</sup> of HPV-related carcinoma *in situ* (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$1,791	\$1,019	\$1,791	\$1,071 - \$2,511
1998	\$3,550	\$4,317	\$3,203	\$-584 - \$8,030
1999	\$2,295	\$2,002	\$2,295	\$879 - \$3,711
2000	\$3,911	\$4,858	\$2,168	\$799 - \$7,022
2001	\$1,914	\$2,919	\$697	\$-200 - \$5,244
2002	\$-4,986	\$16,571	\$923	\$-1,051 - \$3,554
2003	\$2,513	\$4,400	\$2,513	\$-598 - \$5,624
2004	\$2,107	\$4,745	\$2,097	\$-134 - \$4,085
2005	\$789	\$4,295	\$525	\$-2,092 - \$3,671
2006	\$-80	\$5,389	\$2,096	\$-6,217 - \$3,880
2007	\$3,571	\$3,601	\$3,014	\$678 - \$6,463
2008	\$14,547	\$13,651	\$14,547	\$4,894 - \$24,199
2009	\$3,964	\$22,050	\$5,560	\$1,025 - \$14,854
2010	\$-14,148	\$29,770	\$101	\$-29,492 - \$1,197
2011	\$205	\$4,717	\$439	\$-84 - \$1,025
2012	\$1,929	\$2,436	\$1,218	\$-72 - \$4,641
2013	\$4,063	\$15,969	\$1,192	\$-2,765 - \$3,131
2014	\$2,898	\$3,575	\$1,019	\$-226 - \$6,799
2015	\$3,610	\$4,200	\$2,248	\$429 - \$4,433
<b>Overall</b>	<b>\$1,466</b>	<b>\$11,483</b>	<b>\$1,253</b>	<b>\$-45 - \$4,638</b>

<sup>1</sup> The period for which costs were added was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 57 **Distribution of net direct medical cost<sup>1</sup> of HPV-related invasive cancer (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$24,270	\$37,416	\$19,242	\$1,750 - \$34,934
1998	\$28,495	\$49,487	\$21,016	\$5,484 - \$36,891
1999	\$33,631	\$62,066	\$15,162	\$1,308 - \$54,032
2000	\$25,505	\$47,256	\$21,636	\$3,669 - \$42,209
2001	\$48,384	\$208,928	\$17,944	\$3,231 - \$42,871
2002	\$26,482	\$34,182	\$22,024	\$6,444 - \$50,453
2003	\$18,177	\$88,144	\$20,556	\$6,274 - \$43,817
2004	\$38,038	\$64,373	\$21,292	\$4,736 - \$45,574
2005	\$36,816	\$47,412	\$20,066	\$7,130 - \$58,227
2006	\$25,963	\$42,424	\$12,700	\$165 - \$33,308
2007	\$38,350	\$74,064	\$17,718	\$4,096 - \$47,807
2008	\$39,127	\$80,999	\$16,002	\$4,107 - \$61,977
2009	\$32,683	\$60,373	\$18,937	\$4,254 - \$44,128
2010	\$38,490	\$99,302	\$19,048	\$5,045 - \$43,131
2011	\$27,433	\$36,223	\$14,385	\$4,902 - \$42,561
2012	\$32,273	\$58,507	\$11,996	\$7,046 - \$30,771
2013	\$24,051	\$37,912	\$17,283	\$5,705 - \$43,135
2014	\$24,516	\$39,853	\$14,452	\$4,259 - \$47,549
2015	\$19,897	\$31,470	\$12,295	\$3,950 - \$31,498
<b>Overall</b>	<b>\$30,382</b>	<b>\$72,834</b>	<b>\$16,411</b>	<b>\$4,527 - \$43,189</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 58 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the anus (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	S	S	S	S
1998	\$19,304	\$17,978	\$14,946	\$3,906 - \$39,061
1999	\$77,158	\$62,950	\$79,233	\$13,197 - \$139,045
2000	S	S	S	S
2002	\$50,274	\$58,751	\$50,274	\$8,731 - \$91,817
2003	S	S	S	S
2004	\$55,135	\$67,206	\$44,567	\$11,136 - \$49,172
2005	\$63,491	\$75,351	\$63,491	\$10,210 - \$116,772
2006	\$16,888	\$15,179	\$13,985	\$3,370 - \$33,308
2007	\$68,051	\$86,985	\$22,064	\$3,887 - \$162,416
2008	\$77,599	\$81,087	\$25,363	\$21,683 - \$146,443
2009	\$63,569	\$56,562	\$62,118	\$15,454 - \$111,684
2010	\$33,631	\$15,111	\$30,410	\$21,421 - \$45,841
2011	\$2,545	\$9,669	\$1,543	\$-5,670 - \$10,760
2012	\$32,871	\$28,105	\$32,871	\$12,998 - \$52,745
2013	\$63,459	\$35,796	\$65,033	\$28,606 - \$105,631
2014	\$8,800	\$95,505	\$70,718	\$-36,877 - \$74,348
2015	\$19,846	\$30,742	\$9,710	\$2,925 - \$18,377
<b>Overall</b>	<b>\$43,629</b>	<b>\$56,467</b>	<b>\$23,712</b>	<b>\$10,213 - \$72,533</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively; S = Suppressed

Supplementary Table 59 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oral cavity (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$21,847	\$33,640	\$20,146	\$539 - \$34,934
1998	\$24,334	\$37,284	\$20,339	\$4,918 - \$26,062
1999	\$31,933	\$79,155	\$15,470	\$335 - \$47,945
2000	\$14,989	\$33,380	\$6,392	\$-580 - \$18,573
2001	\$31,458	\$37,492	\$22,937	\$3,112 - \$47,548
2002	\$25,684	\$42,109	\$27,341	\$3,108 - \$52,256
2003	\$28,914	\$35,140	\$31,332	\$16,367 - \$43,866
2004	\$73,368	\$84,663	\$30,992	\$17,534 - \$85,703
2005	\$52,886	\$40,064	\$49,382	\$16,501 - \$78,667
2006	\$39,716	\$39,040	\$28,578	\$9,818 - \$70,880
2007	\$51,328	\$74,801	\$26,554	\$8,826 - \$72,532
2008	\$78,373	\$111,950	\$61,977	\$16,930 - \$93,706
2009	\$30,532	\$53,812	\$20,174	\$2,147 - \$48,896
2010	\$59,460	\$140,853	\$29,892	\$8,027 - \$64,587
2011	\$46,828	\$44,642	\$42,561	\$14,433 - \$70,784
2012	\$45,102	\$82,013	\$15,167	\$7,248 - \$43,695
2013	\$36,700	\$33,765	\$35,299	\$8,088 - \$47,160
2014	\$34,341	\$34,677	\$19,282	\$10,206 - \$47,549
2015	\$27,949	\$37,108	\$29,790	\$9,247 - \$45,632
<b>Overall</b>	<b>\$40,669</b>	<b>\$67,962</b>	<b>\$27,175</b>	<b>\$7,307 - \$57,202</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 60 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the oropharynx (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$15,635	\$25,111	\$15,236	\$5,979 - \$26,010
1998	\$34,634	\$66,401	\$28,616	\$9,672 - \$53,995
1999	\$35,369	\$45,167	\$27,997	\$1,182 - \$69,854
2000	\$42,443	\$56,695	\$41,904	\$22,992 - \$56,940
2001	\$77,767	\$310,734	\$21,286	\$2,889 - \$43,330
2002	\$21,400	\$24,544	\$20,030	\$6,444 - \$34,012
2003	\$11,998	\$124,497	\$19,261	\$5,596 - \$47,405
2004	\$10,917	\$28,731	\$14,415	\$-2,114 - \$21,970
2005	\$21,771	\$51,238	\$16,843	\$4,645 - \$25,971
2006	\$17,778	\$47,418	\$6,291	\$-2,372 - \$17,476
2007	\$28,568	\$78,370	\$12,892	\$3,053 - \$32,445
2008	\$9,251	\$34,842	\$10,553	\$-4,552 - \$22,945
2009	\$30,418	\$68,177	\$10,917	\$2,028 - \$42,474
2010	\$20,232	\$28,951	\$11,153	\$4,694 - \$28,693
2011	\$18,433	\$27,674	\$7,806	\$4,587 - \$24,514
2012	\$23,389	\$31,277	\$11,593	\$4,344 - \$29,873
2013	\$13,805	\$36,676	\$10,402	\$709 - \$27,071
2014	\$17,402	\$23,568	\$11,673	\$2,954 - \$20,254
2015	\$15,671	\$19,315	\$9,123	\$4,740 - \$18,613
<b>Overall</b>	<b>\$23,530</b>	<b>\$84,366</b>	<b>\$12,551</b>	<b>\$3,683 - \$29,873</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 61 **Distribution of net direct medical cost<sup>1</sup> of invasive cancer of the penis (for patients compared to their matches) in 2017 Canadian dollars among Manitoba males by year of diagnosis (1997-2015)**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	\$110,095	\$68,650	\$110,095	\$61,552 - \$158,637
1998	S	S	S	S
1999	\$16,355	\$28,533	\$8,161	\$1,308 - \$14,854
2000	\$7,300	\$45,010	\$18,573	\$2,685 - \$24,807
2001	\$10,409	\$28,597	\$7,120	\$4,537 - \$27,283
2002	\$44,463	\$36,508	\$45,229	\$12,920 - \$76,006
2003	\$10,948	\$28,026	\$-92	\$-5,465 - \$12,533
2004	\$9,305	\$12,899	\$4,736	\$3,097 - \$5,043
2005	\$7,862	\$11,432	\$7,467	\$-3,367 - \$19,487
2006	\$4,253	\$6,779	\$3,269	\$-1,981 - \$11,469
2007	\$10,473	\$9,764	\$11,904	\$4,937 - \$17,718
2008	\$3,751	\$6,881	\$4,340	\$-2,146 - \$5,616
2009	\$20,798	\$279	\$20,798	\$20,601 - \$20,996
2010	\$-6,669	\$32,583	\$-6,669	\$-29,709 - \$16,370
2011	\$16,962	\$13,615	\$16,264	\$12,134 - \$16,718
2012	\$13,895	\$10,260	\$9,820	\$9,411 - \$15,435
2013	\$6,205	\$23,502	\$9,417	\$3,555 - \$19,514
2014	\$37,072	\$45,472	\$26,507	\$4,353 - \$73,214
2015	\$14,037	\$39,968	\$7,224	\$-5,487 - \$19,021
<b>Overall</b>	<b>\$16,486</b>	<b>\$33,336</b>	<b>\$9,417</b>	<b>\$2,806 - \$21,572</b>

<sup>1</sup> The period for which costs were added was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively; S = Suppressed

### Healthcare utilization

Supplementary Table 62 **Average number of healthcare encounters<sup>1</sup> (per year) of HPV-related disease patients and their matches among Manitoba males (1997-2015)**

HPV-related disease	Patients				Matches			
	Clinician visits	Hospital admissions	ER visits <sup>2</sup>	Prescriptions	Clinician visits	Hospital admissions	ER visits <sup>2</sup>	Prescriptions
Anogenital warts	8.9	0.2	0.3	8.9	4.3	0.1	0.2	6.3
All HPV-related carcinoma <i>in situ</i>	17.9	1.1	0.5	29.2	9.5	0.3	0.4	20.2
All HPV-related invasive cancers	19.9	1.3	0.8	34.8	9.0	0.3	0.3	21.4
Invasive cancer of the anus	24.7	1.9	2.2	94.6	8.1	0.2	0.2	20.0
Invasive cancer of the oral cavity	19.8	1.3	0.7	32.5	9.1	0.3	0.3	20.7
Invasive cancer of the oropharynx	20.0	1.3	0.6	27.0	8.7	0.3	0.3	20.0
Invasive cancer of the penis	17.6	1.4	0.6	36.9	10.2	0.3	0.4	29.3
<b>Total</b>	<b>10.5</b>	<b>0.4</b>	<b>0.4</b>	<b>12.6</b>	<b>4.9</b>	<b>0.1</b>	<b>0.2</b>	<b>8.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer;

<sup>2</sup> ER visits are for the Winnipeg Regional Health Authority only

Supplementary Table 63 **Excess number of healthcare encounters<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males (1997-2015)**

<b>HPV-related disease</b>	<b>Clinician visits</b>	<b>Hospital admissions</b>	<b>ER visits<sup>2</sup></b>	<b>Prescriptions</b>
Anogenital warts	67,637	2,218	1,118	35,618
All HPV-related carcinoma <i>in situ</i>	733	66	-3	811
All HPV-related invasive cancers	11,665	1,174	319	13,811
Invasive cancer of the anus	1,167	126	107	5,747
Invasive cancer of the oral cavity	4,330	425	88	5,107
Invasive cancer of the oropharynx	5,224	478	113	2,089
Invasive cancer of the penis	943	145	11	868
<b>Total</b>	<b>80,034</b>	<b>3,458</b>	<b>1,434</b>	<b>50,239</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer;

<sup>2</sup> ER visits are for the Winnipeg Regional Health Authority only



Supplementary Table 64 **Distribution of excess number of healthcare encounters<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males (1997-2015)**

<b>HPV-related disease</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
<b>Excess clinician visits</b>				
Anogenital warts	4.6	9.7	3.0	-0.3 - 7.7
All HPV-related carcinoma <i>in situ</i>	8.6	11.1	4.8	1.2 - 15.8
All HPV-related invasive cancers	10.2	15.4	8.8	3.0 - 16.7
Invasive cancer of the anus	16.2	20.6	14.4	6.9 - 23.6
Invasive cancer of the oral cavity	10.1	16.2	8.1	2.1 - 15.5
Invasive cancer of the oropharynx	10.2	13.8	9.3	3.7 - 17.5
Invasive cancer of the penis	6.8	14.7	6.5	0.7 - 12.9
<b>Excess hospital admissions</b>				
Anogenital warts	0.2	0.7	0.0	0.0 - 0.0
All HPV-related carcinoma <i>in situ</i>	0.8	1.0	0.7	0.0 - 1.3
All HPV-related invasive cancers	1.0	1.2	0.8	0.4 - 1.6
Invasive cancer of the anus	1.8	1.6	1.4	0.7 - 2.4
Invasive cancer of the oral cavity	1.0	1.1	0.8	0.4 - 1.6
Invasive cancer of the oropharynx	0.9	1.2	0.7	0.3 - 1.4
Invasive cancer of the penis	1.0	1.0	0.8	0.4 - 1.6
<b>Excess ER visits<sup>4</sup></b>				
Anogenital warts	0.1	1.2	0.0	-0.3 - 0.0
All HPV-related carcinoma <i>in situ</i>	-0.0	1.3	0.0	-0.3 - 0.0
All HPV-related invasive cancers	0.5	2.1	0.0	-0.1 - 0.5
Invasive cancer of the anus	2.2	6.2	0.4	0.0 - 1.5
Invasive cancer of the oral cavity	0.3	1.4	0.0	-0.1 - 0.5
Invasive cancer of the oropharynx	0.4	1.2	0.0	-0.1 - 0.4
Invasive cancer of the penis	0.2	0.8	0.0	-0.1 - 0.4
<b>Excess prescriptions</b>				
Anogenital warts	2.4	25.9	0.0	-2.3 - 4.0
All HPV-related carcinoma <i>in situ</i>	9.6	49.6	1.8	-10.0 - 14.2
All HPV-related invasive cancers	12.2	91.5	6.0	-7.9 - 24.6
Invasive cancer of the anus	79.8	266.5	9.2	-1.5 - 46.8
Invasive cancer of the oral cavity	11.9	67.3	6.8	-7.9 - 25.0
Invasive cancer of the oropharynx	4.1	58.5	4.9	-7.1 - 20.9
Invasive cancer of the penis	6.3	50.6	1.2	-15.1 - 28.0

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively; <sup>4</sup> ER visits are for the Winnipeg Regional Health Authority only

### Excess healthcare utilization by age

Supplementary Table 65 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
9 - 17	3.5	5.8	2.3	0.0 - 6.0
18 - 30	4.2	7.4	3.0	0.3 - 6.7
31 - 50	4.7	10.5	2.7	-0.7 - 8.3
51 - 64	6.2	14.9	4.0	-1.0 - 11.0
≥65	6.7	18.0	5.3	-1.3 - 14.0
<b>Overall</b>	<b>4.6</b>	<b>9.7</b>	<b>3.0</b>	<b>-0.3 - 7.7</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 66 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
9 - 17	0.2	0.6	0.0	0.0 - 0.0
18 - 30	0.1	0.5	0.0	0.0 - 0.0
31 - 50	0.2	0.7	0.0	0.0 - 0.0
51 - 64	0.3	1.1	0.0	0.0 - 0.7
≥65	0.6	1.3	0.0	0.0 - 1.0
<b>Overall</b>	<b>0.2</b>	<b>0.7</b>	<b>0.0</b>	<b>0.0 - 0.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 67 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
9 - 17	0.1	1.0	0.0	-0.3 - 0.0
18 - 30	0.1	1.0	0.0	-0.3 - 0.0
31 - 50	0.1	1.3	0.0	-0.3 - 0.0

51 - 64	0.1	1.1	0.0	-0.3 - 0.0
≥65	0.2	3.1	0.0	-0.3 - 0.0
<b>Overall</b>	<b>0.1</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 68 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
9 - 17	0.9	9.5	0.0	-1.7 - 2.7
18 - 30	1.0	14.0	0.0	-1.7 - 3.0
31 - 50	3.4	29.9	0.0	-3.3 - 5.3
51 - 64	7.1	44.0	1.0	-8.7 - 15.0
≥65	4.5	61.4	2.0	-12.3 - 25.7
<b>Overall</b>	<b>2.4</b>	<b>25.9</b>	<b>0.0</b>	<b>-2.3 - 4.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 69 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	5.3	7.9	4.3	1.7 - 9.0
31 - 50	8.8	11.8	4.3	1.3 - 14.5
51 - 64	5.2	7.7	4.0	-0.8 - 11.5
≥65	12.6	13.2	14.0	3.3 - 20.7
<b>Overall</b>	<b>8.6</b>	<b>11.1</b>	<b>4.8</b>	<b>1.2 - 15.8</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 70 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
-------------	---------	-----------------	--------	----------------------

18 - 30	0.3	0.9	0.0	0.0 - 1.0
31 - 50	0.6	0.9	0.0	0.0 - 1.5
51 - 64	0.8	0.8	0.7	0.3 - 1.0
≥65	0.9	1.3	1.0	-0.3 - 1.7
<b>Overall</b>	<b>0.8</b>	<b>1.0</b>	<b>0.7</b>	<b>0.0 - 1.3</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 71 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
18 - 30	0.1	2.3	-0.7	-0.7 - -0.3
31 - 50	0.3	0.9	0.0	0.0 - 0.7
51 - 64	-0.2	0.5	0.0	-0.3 - 0.0
≥65	-0.1	1.8	0.0	-0.8 - 0.8
<b>Overall</b>	<b>-0.0</b>	<b>1.3</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 72 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	-7.0	25.1	0.7	-1.0 - 4.3
31 - 50	21.8	41.7	5.2	0.2 - 23.7
51 - 64	9.2	39.9	-0.5	-10.0 - 7.0
≥65	7.2	64.6	4.3	-23.0 - 27.7
<b>Overall</b>	<b>9.6</b>	<b>49.6</b>	<b>1.8</b>	<b>-10.0 - 14.2</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 73 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	12.6	8.0	6.9	6.9 - 18.5
31 - 50	12.6	16.9	9.5	4.4 - 17.5
51 - 64	10.5	12.8	9.2	3.6 - 16.6
≥65	8.7	17.2	7.9	1.5 - 15.6
<b>Overall</b>	<b>10.2</b>	<b>15.4</b>	<b>8.8</b>	<b>3.0 - 16.7</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 74 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	1.1	0.6	1.1	0.8 - 1.6
31 - 50	1.1	1.2	0.8	0.4 - 1.5
51 - 64	1.0	1.0	0.8	0.4 - 1.5
≥65	1.0	1.3	0.8	0.2 - 1.6
<b>Overall</b>	<b>1.0</b>	<b>1.2</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 75 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
18 - 30	1.2	1.3	1.2	0.3 - 2.1
31 - 50	0.7	3.9	0.0	-0.1 - 0.4
51 - 64	0.4	1.4	0.1	-0.1 - 0.5
≥65	0.4	1.7	0.0	-0.1 - 0.8
<b>Overall</b>	<b>0.5</b>	<b>2.1</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 76 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	13.4	11.2	16.9	1.6 - 21.2
31 - 50	16.2	33.7	6.2	-0.4 - 23.5
51 - 64	17.9	112.0	6.3	-5.9 - 22.7
≥65	4.1	84.2	3.6	-15.6 - 26.5
<b>Overall</b>	<b>12.2</b>	<b>91.5</b>	<b>6.0</b>	<b>-7.9 - 24.6</b>



<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 77 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	27.1	25.7	16.1	11.7 - 30.7
51 - 64	13.0	12.0	10.3	5.0 - 18.9
≥65	14.8	26.4	13.2	10.3 - 26.0
<b>Overall</b>	<b>16.2</b>	<b>20.6</b>	<b>14.4</b>	<b>6.9 - 23.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 78 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	2.5	2.6	1.8	0.8 - 2.9
51 - 64	1.5	1.3	1.3	0.5 - 2.4
≥65	1.6	1.0	1.5	0.8 - 2.2
<b>Overall</b>	<b>1.8</b>	<b>1.6</b>	<b>1.4</b>	<b>0.7 - 2.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 79 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
31 - 50	6.1	12.5	1.5	0.0 - 4.0
51 - 64	1.3	3.2	0.5	0.0 - 1.2
≥65	1.2	2.7	0.4	0.1 - 1.2
<b>Overall</b>	<b>2.2</b>	<b>6.2</b>	<b>0.4</b>	<b>0.0 - 1.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 80 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	56.1	58.1	38.9	8.4 - 94.2
51 - 64	122.7	367.8	6.5	-8.1 - 61.6
≥65	25.4	79.0	8.1	-0.8 - 27.0
<b>Overall</b>	<b>79.8</b>	<b>266.5</b>	<b>9.2</b>	<b>-1.5 - 46.8</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 81 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	15.2	11.9	15.2	6.8 - 23.6
31 - 50	11.9	22.3	8.3	3.0 - 12.7
51 - 64	9.6	13.8	8.6	2.4 - 16.4
≥65	9.8	15.7	7.8	1.2 - 15.4
<b>Overall</b>	<b>10.1</b>	<b>16.2</b>	<b>8.1</b>	<b>2.1 - 15.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 82 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	1.1	0.9	1.1	0.4 - 1.7
31 - 50	0.9	0.9	0.7	0.4 - 1.3
51 - 64	0.9	0.9	0.8	0.4 - 1.6
≥65	1.1	1.4	0.8	0.3 - 1.6
<b>Overall</b>	<b>1.0</b>	<b>1.1</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 83 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

<b>Age (years)</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
18 - 30	2.1		2.1	2.1 - 2.1
31 - 50	0.2	0.8	0.0	-0.1 - 0.6
51 - 64	0.2	1.0	0.0	-0.1 - 0.4
≥65	0.5	1.9	0.0	-0.2 - 0.7
<b>Overall</b>	<b>0.3</b>	<b>1.4</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 84 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	11.3	14.0	11.3	1.5 - 21.2
31 - 50	11.7	35.5	1.7	-3.4 - 21.9
51 - 64	10.1	44.5	9.7	-2.3 - 24.0
≥65	13.6	90.8	7.4	-13.3 - 28.4
<b>Overall</b>	<b>11.9</b>	<b>67.3</b>	<b>6.8</b>	<b>-7.9 - 25.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 85 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	11.8	9.6	10.3	5.7 - 17.9
51 - 64	11.4	11.8	9.5	4.5 - 16.8
≥65	7.5	17.9	7.6	2.3 - 16.9
<b>Overall</b>	<b>10.2</b>	<b>13.8</b>	<b>9.3</b>	<b>3.7 - 17.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 86 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	1.1	1.0	0.8	0.4 - 1.3
51 - 64	0.9	1.1	0.7	0.3 - 1.3
≥65	0.9	1.4	0.5	0.0 - 1.6
<b>Overall</b>	<b>0.9</b>	<b>1.2</b>	<b>0.7</b>	<b>0.3 - 1.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 87 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
31 - 50	0.2	0.8	0.0	-0.1 - 0.4
51 - 64	0.4	1.2	0.1	0.0 - 0.4
≥65	0.3	1.5	0.0	-0.2 - 0.8
<b>Overall</b>	<b>0.4</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 88 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
31 - 50	15.0	25.6	7.3	0.9 - 22.5
51 - 64	8.6	40.9	4.9	-5.9 - 20.7
≥65	-9.9	87.6	1.6	-22.1 - 21.2
<b>Overall</b>	<b>4.1</b>	<b>58.5</b>	<b>4.9</b>	<b>-7.1 - 20.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 89 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	10.8	6.7	6.9	6.9 - 18.5
31 - 50	8.3	10.9	5.7	2.4 - 16.3
51 - 64	5.2	14.5	6.4	0.7 - 11.5
≥65	7.0	15.7	6.5	-0.3 - 13.2
<b>Overall</b>	<b>6.8</b>	<b>14.7</b>	<b>6.5</b>	<b>0.7 - 12.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 90 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	1.2	0.4	1.1	0.8 - 1.6
31 - 50	1.1	1.1	0.7	0.4 - 1.3
51 - 64	1.0	1.0	0.7	0.4 - 1.2
≥65	1.1	1.0	0.8	0.4 - 1.6
<b>Overall</b>	<b>1.0</b>	<b>1.0</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 91 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>3</sup>	Median	Q1 - Q3 <sup>4</sup>
18 - 30	0.3		0.3	0.3 - 0.3
31 - 50	0.1	0.2	0.0	0.0 - 0.3
51 - 64	0.1	0.8	0.3	-0.1 - 0.5
≥65	0.2	0.9	0.0	-0.4 - 0.5
<b>Overall</b>	<b>0.2</b>	<b>0.8</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 92 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by age group (1997-2015).**

Age (years)	Average	SD <sup>2</sup>	Median	Q1 - Q3 <sup>3</sup>
18 - 30	14.7	12.2	16.9	1.6 - 25.6
31 - 50	8.4	21.2	3.9	-2.8 - 17.6
51 - 64	10.6	41.3	-2.7	-11.2 - 28.0
≥65	4.1	57.8	1.3	-26.1 - 31.9
<b>Overall</b>	<b>6.3</b>	<b>50.6</b>	<b>1.2</b>	<b>-15.1 - 28.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



**Excess healthcare utilization by regional health authority and Winnipeg region of residence**

Supplementary Table 93 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	4.7	10.2	3.0	-0.3 - 8.0
Northern suburbs	4.6	10.7	3.0	-0.3 - 7.7
Inner city	5.2	11.0	3.0	-0.3 - 9.0
Southern suburbs	4.6	9.6	3.0	-0.3 - 8.0
Interlake-Eastern	4.2	9.9	2.7	0.0 - 7.0
Northern	4.0	9.1	2.3	0.0 - 6.0
Southern	4.0	7.0	3.0	0.0 - 7.0
Prairie Mountain	4.4	7.7	3.0	0.0 - 7.3
Public Trustee/In CFS care	5.4	12.6	3.2	-1.7 - 8.0
<b>Overall</b>	<b>4.6</b>	<b>9.7</b>	<b>3.0</b>	<b>-0.3 - 7.7</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 94 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	0.1	0.7	0.0	0.0 - 0.0
Northern suburbs	0.2	0.6	0.0	0.0 - 0.0
Inner city	0.2	1.0	0.0	0.0 - 0.0
Southern suburbs	0.1	0.5	0.0	0.0 - 0.0
Interlake-Eastern	0.2	0.8	0.0	0.0 - 0.0
Northern	0.4	1.0	0.0	0.0 - 1.0
Southern	0.1	0.6	0.0	0.0 - 0.0
Prairie Mountain	0.1	0.6	0.0	0.0 - 0.0
Public Trustee/In CFS care	0.5	1.0	0.0	0.0 - 1.0
<b>Overall</b>	<b>0.2</b>	<b>0.7</b>	<b>0.0</b>	<b>0.0 - 0.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 95 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	0.1	1.2	0.0	-0.3 - 0.0
Northern suburbs	0.2	1.0	0.0	-0.3 - 0.0
Inner city	0.1	2.2	0.0	-0.3 - 0.0
Southern suburbs	0.1	0.8	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.1</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 96 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	2.3	27.0	0.0	-2.3 - 4.0
Northern suburbs	2.9	28.0	0.0	-2.0 - 4.0
Inner city	3.6	35.9	0.0	-3.7 - 5.0
Southern suburbs	1.6	22.2	0.0	-2.3 - 4.0
Interlake-Eastern	2.7	19.9	0.3	-2.3 - 4.0
Northern	4.4	17.4	0.7	-1.7 - 5.7
Southern	2.3	14.6	0.3	-1.7 - 4.0
Prairie Mountain	2.4	30.1	0.0	-2.3 - 4.0
Public Trustee/In CFS care	3.1	48.2	-0.6	-9.0 - 6.7
<b>Overall</b>	<b>2.4</b>	<b>25.9</b>	<b>0.0</b>	<b>-2.3 - 4.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 97 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	9.0	11.6	5.7	1.0 - 16.0
Northern suburbs	11.2	12.5	11.0	1.7 - 17.7
Inner city	13.6	15.5	9.3	2.5 - 25.0
Southern suburbs	5.9	8.4	4.0	0.7 - 12.0
Interlake-Eastern	8.7	8.7	8.0	2.8 - 16.7
Northern	8.8	11.2	6.3	2.0 - 9.7
Southern	-0.1	6.0	3.0	-7.0 - 3.7
Prairie Mountain	5.4	10.9	3.5	-1.8 - 12.7
Public Trustee/In CFS care	21.0		21.0	21.0 - 21.0
<b>Overall</b>	<b>8.6</b>	<b>11.1</b>	<b>4.8</b>	<b>1.2 - 15.8</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 98 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	0.8	1.0	1.0	0.0 - 1.3
Northern suburbs	0.9	0.7	1.0	0.0 - 1.3
Inner city	0.5	1.0	0.5	-0.2 - 1.0
Southern suburbs	0.9	1.1	1.0	0.0 - 1.7
Interlake-Eastern	0.7	1.3	0.3	-0.3 - 1.7
Northern	0.8	0.9	0.7	0.0 - 1.7
Southern	0.3	1.2	1.0	-1.0 - 1.0
Prairie Mountain	0.5	1.9	1.0	-1.0 - 2.0
Public Trustee/In CFS care	0.0		0.0	0.0 - 0.0
<b>Overall</b>	<b>0.8</b>	<b>1.0</b>	<b>0.7</b>	<b>0.0 - 1.3</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 99 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	-0.0	1.3	0.0	-0.3 - 0.0
Northern suburbs	0.3	1.4	0.0	-0.3 - 0.0
Inner city	-0.4	2.1	0.0	-1.3 - 0.5
Southern suburbs	-0.1	0.8	0.0	-0.3 - 0.0
<b>Overall</b>	<b>-0.0</b>	<b>1.3</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 100 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	10.5	52.4	1.2	-10.7 - 16.7
Northern suburbs	5.0	19.9	0.7	-1.7 - 10.7
Inner city	37.5	103.0	44.5	-23.8 - 130.0
Southern suburbs	2.6	28.2	1.0	-10.7 - 6.7
Interlake-Eastern	12.6	66.7	3.2	-23.5 - 22.7
Northern	9.1	29.9	1.0	-5.7 - 7.3
Southern	-7.1	17.6	-13.0	-21.0 - 12.7
Prairie Mountain	6.0	11.2	5.0	-1.2 - 13.2
Public Trustee/In CFS care	-0.7		-0.7	-0.7 - -0.7
<b>Overall</b>	<b>9.6</b>	<b>49.6</b>	<b>1.8</b>	<b>-10.0 - 14.2</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 101 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	9.9	16.4	8.7	2.5 - 16.9
Northern suburbs	8.5	11.7	7.7	2.7 - 14.5
Inner city	12.4	24.1	9.5	3.1 - 21.0
Southern suburbs	9.6	14.5	8.5	2.2 - 16.8
Interlake-Eastern	9.9	10.4	8.5	2.7 - 15.6
Northern	10.5	16.9	7.6	0.1 - 14.6
Southern	11.9	14.8	10.4	6.0 - 18.2
Prairie Mountain	10.5	14.6	8.4	3.3 - 16.3
Public Trustee/In CFS care	8.9	15.7	9.0	6.4 - 11.5
<b>Overall</b>	<b>10.2</b>	<b>15.4</b>	<b>8.8</b>	<b>3.0 - 16.7</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 102 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	1.0	1.3	0.8	0.3 - 1.6
Northern suburbs	1.0	1.5	0.7	0.3 - 1.5
Inner city	1.3	1.4	0.9	0.5 - 1.9
Southern suburbs	0.9	1.0	0.7	0.3 - 1.3
Interlake-Eastern	1.0	1.1	0.7	0.3 - 1.6
Northern	1.2	1.2	0.8	0.4 - 1.6
Southern	1.1	1.1	0.8	0.4 - 1.6
Prairie Mountain	1.1	1.0	0.8	0.4 - 1.6
Public Trustee/In CFS care	0.2	0.6	0.3	-0.4 - 0.6
<b>Overall</b>	<b>1.0</b>	<b>1.2</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 103 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	0.5	2.1	0.0	-0.1 - 0.5
Northern suburbs	0.3	1.1	0.0	-0.1 - 0.5
Inner city	1.0	4.2	0.0	-0.1 - 0.8
Southern suburbs	0.3	1.1	0.0	-0.1 - 0.6
<b>Overall</b>	<b>0.5</b>	<b>2.1</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 104 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	11.2	88.9	5.1	-7.9 - 22.3
Northern suburbs	-3.5	74.2	4.1	-9.7 - 18.2
Inner city	36.5	161.7	9.1	-11.4 - 42.7
Southern suburbs	8.8	40.3	4.3	-5.3 - 19.5
Interlake-Eastern	8.5	33.9	3.9	-8.9 - 21.9
Northern	5.4	38.4	1.6	-9.3 - 25.4
Southern	14.6	40.2	10.9	-3.3 - 24.3
Prairie Mountain	18.0	148.7	6.7	-15.2 - 29.6
Public Trustee/In CFS care	48.3	66.2	52.5	17.7 - 69.2
<b>Overall</b>	<b>12.2</b>	<b>91.5</b>	<b>6.0</b>	<b>-7.9 - 24.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 105 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	14.7	22.6	10.9	5.5 - 19.1
Northern suburbs	13.3	14.6	10.9	10.3 - 16.7
Inner city	26.5	24.7	17.5	9.3 - 32.5
Southern suburbs	7.9	22.2	9.7	4.8 - 17.2
Interlake-Eastern	23.0	15.8	17.7	8.5 - 31.2
Northern	8.5	12.3	8.5	-0.2 - 17.2
Southern	21.8	5.9	21.7	16.0 - 27.7
Prairie Mountain	21.0	14.7	15.7	12.7 - 28.4
<b>Overall</b>	<b>16.2</b>	<b>20.6</b>	<b>14.4</b>	<b>6.9 - 23.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 106 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	1.8	1.7	1.3	0.7 - 2.4
Northern suburbs	1.3	1.0	0.9	0.4 - 2.1
Inner city	2.8	2.4	2.0	1.1 - 3.2
Southern suburbs	1.4	1.0	1.3	0.7 - 2.4
Interlake-Eastern	1.6	1.3	1.6	0.7 - 2.4
Northern	1.0	0.0	1.0	1.0 - 1.1
Southern	2.5	1.8	2.9	0.5 - 4.1
Prairie Mountain	1.6	1.1	2.0	0.8 - 2.4
<b>Overall</b>	<b>1.8</b>	<b>1.6</b>	<b>1.4</b>	<b>0.7 - 2.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 107 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	2.2	6.2	0.4	0.0 - 1.5
Northern suburbs	0.5	0.6	0.4	0.0 - 1.2
Inner city	5.8	10.6	1.2	0.1 - 9.1
Southern suburbs	0.7	1.0	0.3	0.0 - 1.6
<b>Overall</b>	<b>2.2</b>	<b>6.2</b>	<b>0.4</b>	<b>0.0 - 1.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 108 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	74.0	258.2	8.8	-1.6 - 65.5
Northern suburbs	25.4	112.3	6.0	-13.7 - 9.6
Inner city	173.3	451.3	39.0	9.2 - 115.6
Southern suburbs	35.0	67.2	5.1	-2.4 - 37.9
Interlake-Eastern	32.1	67.2	7.5	-10.9 - 47.6
Northern	11.4	21.8	11.4	-4.0 - 26.8
Southern	34.2	23.1	33.2	11.6 - 57.7
Prairie Mountain	256.4	545.5	21.6	7.1 - 27.2
<b>Overall</b>	<b>79.8</b>	<b>266.5</b>	<b>9.2</b>	<b>-1.5 - 46.8</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 109 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	10.2	17.7	7.9	1.7 - 16.3
Northern suburbs	7.9	13.0	6.1	0.7 - 13.3
Inner city	10.5	29.1	6.1	0.9 - 15.5
Southern suburbs	11.2	13.5	8.9	2.2 - 18.4
Interlake-Eastern	7.0	9.3	6.8	0.1 - 12.5
Northern	7.0	13.4	5.7	0.1 - 10.8
Southern	12.0	9.0	10.5	6.0 - 17.3
Prairie Mountain	12.4	17.6	10.2	2.5 - 16.3
Public Trustee/In CFS care	3.8	12.5	9.0	6.4 - 10.6
<b>Overall</b>	<b>10.1</b>	<b>16.2</b>	<b>8.1</b>	<b>2.1 - 15.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 110 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	1.0	1.2	0.8	0.3 - 1.4
Northern suburbs	1.0	1.8	0.5	0.3 - 1.3
Inner city	1.1	0.8	0.9	0.7 - 1.6
Southern suburbs	0.9	1.1	0.7	0.3 - 1.4
Interlake-Eastern	1.0	0.9	0.8	0.4 - 1.6
Northern	1.1	0.8	1.2	0.4 - 1.7
Southern	1.1	0.8	1.0	0.5 - 1.9
Prairie Mountain	1.1	1.0	0.8	0.4 - 2.0
Public Trustee/In CFS care	0.2	0.7	0.3	-0.4 - 0.6
<b>Overall</b>	<b>1.0</b>	<b>1.1</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 111 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	0.3	1.4	0.0	-0.1 - 0.5
Northern suburbs	0.2	0.9	0.0	-0.1 - 0.4
Inner city	0.6	2.4	0.0	-0.1 - 0.8
Southern suburbs	0.3	1.1	0.0	-0.1 - 0.7
<b>Overall</b>	<b>0.3</b>	<b>1.4</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 112 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	8.7	60.0	9.6	-8.0 - 25.6
Northern suburbs	-7.4	79.8	5.9	-10.4 - 20.0
Inner city	21.7	62.2	11.5	-26.4 - 64.9
Southern suburbs	11.5	45.1	10.1	-2.9 - 24.6
Interlake-Eastern	1.3	29.0	-0.5	-14.3 - 6.8
Northern	-3.0	40.8	0.5	-8.9 - 12.2
Southern	10.5	23.8	9.9	-4.0 - 23.2
Prairie Mountain	41.0	127.6	7.2	-2.5 - 40.3
Public Trustee/In CFS care	42.1	80.0	45.1	17.7 - 52.5
<b>Overall</b>	<b>11.9</b>	<b>67.3</b>	<b>6.8</b>	<b>-7.9 - 25.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 113 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	9.8	13.9	10.0	3.5 - 17.6
Northern suburbs	9.0	10.5	9.6	4.7 - 16.0
Inner city	12.7	19.9	16.1	5.3 - 26.8
Southern suburbs	9.2	13.1	8.5	2.5 - 15.7
Interlake-Eastern	10.4	8.8	9.3	3.1 - 16.6
Northern	14.6	20.1	10.0	5.2 - 15.7
Southern	9.7	19.6	9.0	5.4 - 15.9
Prairie Mountain	11.5	9.7	9.2	5.7 - 17.7
<b>Overall</b>	<b>10.2</b>	<b>13.8</b>	<b>9.3</b>	<b>3.7 - 17.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 114 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	0.9	1.2	0.7	0.3 - 1.3
Northern suburbs	1.1	1.4	0.5	0.3 - 1.5
Inner city	1.0	1.3	0.9	0.4 - 1.9
Southern suburbs	0.8	1.0	0.7	0.3 - 1.2
Interlake-Eastern	0.8	1.3	0.7	0.1 - 1.5
Northern	1.2	1.3	0.8	0.3 - 1.2
Southern	0.7	1.0	0.6	0.2 - 1.2
Prairie Mountain	1.2	1.0	1.0	0.4 - 1.6
<b>Overall</b>	<b>0.9</b>	<b>1.2</b>	<b>0.7</b>	<b>0.3 - 1.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 115 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	0.4	1.2	0.0	-0.1 - 0.4
Northern suburbs	0.4	1.4	0.0	-0.1 - 0.5
Inner city	0.4	1.5	0.0	-0.1 - 0.4
Southern suburbs	0.3	1.0	0.0	-0.1 - 0.5
<b>Overall</b>	<b>0.4</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 116 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	5.4	47.6	4.1	-6.7 - 17.6
Northern suburbs	-3.6	67.4	3.5	-8.4 - 21.3
Inner city	23.2	57.5	8.3	-4.0 - 31.5
Southern suburbs	4.2	23.8	2.8	-6.5 - 13.1
Interlake-Eastern	11.5	32.0	12.5	-6.7 - 25.9
Northern	15.7	38.8	10.1	-9.3 - 34.9
Southern	9.7	40.5	5.3	-3.7 - 19.6
Prairie Mountain	-17.2	116.0	3.7	-25.9 - 24.0
<b>Overall</b>	<b>4.1</b>	<b>58.5</b>	<b>4.9</b>	<b>-7.1 - 20.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 117 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	4.9	14.4	5.6	-2.4 - 12.0
Northern suburbs	5.0	9.4	5.6	2.3 - 10.1
Inner city	4.3	9.8	5.5	-2.4 - 8.7
Southern suburbs	5.1	19.3	5.0	-3.1 - 15.1
Interlake-Eastern	9.6	11.7	7.6	0.4 - 13.4
Northern	5.0	12.7	7.8	-4.1 - 14.1
Southern	15.5	14.7	13.6	4.4 - 32.2
Prairie Mountain	5.4	15.4	6.5	1.3 - 12.9
Public Trustee/In CFS care	21.7	19.6	21.7	7.9 - 35.6
<b>Overall</b>	<b>6.8</b>	<b>14.7</b>	<b>6.5</b>	<b>0.7 - 12.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 118 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	1.1	0.9	0.8	0.4 - 1.6
Northern suburbs	1.1	0.9	0.9	0.4 - 1.6
Inner city	1.3	0.8	1.2	0.8 - 1.7
Southern suburbs	1.0	1.1	0.7	0.4 - 1.2
Interlake-Eastern	1.2	0.9	0.9	0.6 - 1.5
Northern	1.3	2.1	0.5	0.1 - 2.5
Southern	1.6	1.1	1.6	0.7 - 2.0
Prairie Mountain	0.8	0.9	0.7	0.3 - 1.5
Public Trustee/In CFS care	0.3	0.0	0.3	0.3 - 0.3
<b>Overall</b>	<b>1.0</b>	<b>1.0</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 119 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
Winnipeg	0.2	0.8	0.0	-0.1 - 0.4
Northern suburbs	0.3	0.7	0.0	0.0 - 0.3
Inner city	0.0	0.8	0.1	-0.5 - 0.4
Southern suburbs	0.2	0.9	0.1	-0.1 - 0.5
<b>Overall</b>	<b>0.2</b>	<b>0.8</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 120 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by regional health authority and Winnipeg region of residence (1997-2015).**

<b>Region</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
Winnipeg	-3.2	49.3	-2.6	-14.1 - 16.1
Northern suburbs	-9.1	50.4	1.6	-15.1 - 8.9
Inner city	-0.6	39.4	-2.6	-12.8 - 4.2
Southern suburbs	-1.2	55.7	-4.5	-26.1 - 17.6
Interlake-Eastern	4.3	24.5	0.2	-10.1 - 19.2
Northern	-16.5	27.8	-7.2	-34.4 - 1.3
Southern	36.5	70.5	22.3	-3.0 - 46.7
Prairie Mountain	10.1	50.7	6.3	-28.5 - 47.5
Public Trustee/In CFS care	64.0	7.4	64.0	58.7 - 69.2
<b>Overall</b>	<b>6.3</b>	<b>50.6</b>	<b>1.2</b>	<b>-15.1 - 28.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

**Excess healthcare utilization by year of diagnosis**

Supplementary Table 121 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	4.8	9.1	3.0	-0.3 - 8.0
1998	3.9	9.5	2.7	-0.7 - 7.3
1999	3.7	8.7	2.7	-1.0 - 6.7
2000	4.4	8.6	3.0	0.0 - 8.0
2001	4.6	11.0	3.0	-0.7 - 6.7
2002	3.7	9.0	2.3	-0.7 - 7.0
2003	4.2	9.0	2.7	-0.3 - 7.0
2004	4.6	9.0	3.3	0.3 - 7.3
2005	4.0	9.4	2.3	-0.3 - 6.7
2006	4.0	8.1	2.7	-0.3 - 7.0
2007	5.3	10.3	3.3	0.0 - 8.3
2008	4.7	8.9	3.3	0.3 - 8.0
2009	4.5	10.7	2.7	-0.3 - 7.0
2010	4.7	8.7	3.0	-0.3 - 8.3
2011	5.2	10.7	3.3	0.0 - 8.3
2012	4.8	10.3	3.0	-0.3 - 7.7
2013	4.8	11.1	3.0	0.0 - 7.3
2014	5.2	9.6	3.7	0.3 - 8.3
2015	5.0	11.1	3.3	-0.3 - 8.7
<b>Overall</b>	<b>4.6</b>	<b>9.7</b>	<b>3.0</b>	<b>-0.3 - 7.7</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 122 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	0.3	0.7	0.0	0.0 - 0.7
1998	0.3	0.8	0.0	0.0 - 0.7
1999	0.2	0.6	0.0	0.0 - 0.0
2000	0.3	0.8	0.0	0.0 - 0.7
2001	0.3	1.2	0.0	0.0 - 0.0
2002	0.1	0.6	0.0	0.0 - 0.0
2003	0.2	0.6	0.0	0.0 - 0.0
2004	0.2	0.7	0.0	0.0 - 0.0
2005	0.1	0.6	0.0	0.0 - 0.0
2006	0.1	0.6	0.0	0.0 - 0.0
2007	0.1	0.7	0.0	0.0 - 0.0
2008	0.2	1.0	0.0	0.0 - 0.0
2009	0.1	0.6	0.0	0.0 - 0.0
2010	0.1	0.5	0.0	0.0 - 0.0
2011	0.1	0.5	0.0	0.0 - 0.0
2012	0.1	0.5	0.0	0.0 - 0.0
2013	0.1	0.5	0.0	0.0 - 0.0
2014	0.1	0.6	0.0	0.0 - 0.0
2015	0.1	0.6	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.2</b>	<b>0.7</b>	<b>0.0</b>	<b>0.0 - 0.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 123 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.0	0.0	0.0	0.0 - 0.0
1998	0.0	0.3	0.0	0.0 - 0.0
1999	0.0	0.9	0.0	-0.3 - 0.0
2000	0.2	1.1	0.0	-0.3 - 0.0
2001	0.1	1.1	0.0	-0.3 - 0.0
2002	0.1	1.1	0.0	-0.3 - 0.0
2003	0.1	1.0	0.0	-0.3 - 0.0
2004	0.2	2.7	0.0	-0.3 - 0.0
2005	0.2	1.3	0.0	-0.3 - 0.0
2006	0.1	1.0	0.0	-0.3 - 0.0
2007	0.1	1.1	0.0	-0.3 - 0.0
2008	0.1	1.3	0.0	-0.3 - 0.0
2009	0.0	2.1	0.0	-0.3 - 0.0
2010	0.1	1.0	0.0	-0.3 - 0.0
2011	0.1	0.9	0.0	-0.3 - 0.0
2012	0.1	1.0	0.0	-0.3 - 0.0
2013	0.1	1.4	0.0	-0.3 - 0.0
2014	0.2	1.0	0.0	0.0 - 0.0
2015	0.0	0.1	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.1</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 124 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to anogenital warts (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	3.2	16.1	0.3	-1.3 - 3.7
1998	3.0	17.1	0.3	-1.7 - 4.0
1999	0.9	12.3	0.0	-2.3 - 2.7
2000	2.7	20.1	0.0	-2.0 - 4.0
2001	2.9	17.0	0.0	-2.0 - 3.0
2002	0.8	19.2	0.0	-2.3 - 3.0
2003	3.3	23.9	0.0	-2.0 - 3.7
2004	2.6	21.4	0.3	-2.0 - 4.0
2005	0.7	17.3	0.0	-2.7 - 3.7
2006	0.7	20.9	0.0	-2.7 - 4.0
2007	2.7	23.3	0.3	-2.0 - 4.0
2008	1.6	31.9	0.3	-2.3 - 5.0
2009	2.8	35.4	0.0	-2.7 - 4.3
2010	2.8	22.9	0.3	-2.7 - 4.3
2011	3.3	26.9	0.3	-2.3 - 5.0
2012	2.5	32.0	0.0	-2.7 - 4.0
2013	1.3	30.5	0.3	-2.7 - 5.0
2014	3.4	35.2	0.0	-2.7 - 5.0
2015	3.9	35.0	0.3	-3.3 - 5.3
<b>Overall</b>	<b>2.4</b>	<b>25.9</b>	<b>0.0</b>	<b>-2.3 - 4.0</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for AGW; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 125 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	3.8	1.6	3.8	2.7 - 5.0
1998	12.2	8.2	13.0	3.7 - 20.0
1999	5.2	1.6	5.2	4.0 - 6.3
2000	13.8	8.0	15.3	7.2 - 20.3
2001	8.4	18.7	-2.0	-2.7 - 30.0
2002	18.8	8.5	17.5	14.0 - 26.3
2003	8.2	8.7	8.2	2.0 - 14.3
2004	4.0	8.8	3.3	0.7 - 9.0
2005	6.7	14.0	0.3	-1.0 - 14.3
2006	3.9	13.7	-2.7	-5.3 - 19.7
2007	1.3	4.2	2.5	-1.7 - 4.2
2008	16.7	0.0	16.7	16.7 - 16.7
2009	16.7	13.5	11.0	9.7 - 17.7
2010	6.3	17.1	-0.2	-5.2 - 17.7
2011	12.3	19.8	4.0	2.0 - 15.7
2012	7.9	12.2	6.7	-3.7 - 20.7
2013	7.5	9.5	7.5	0.0 - 17.3
2014	5.2	7.5	4.7	1.0 - 10.7
2015	4.1	4.2	4.0	2.0 - 4.0
<b>Overall</b>	<b>8.6</b>	<b>11.1</b>	<b>4.8</b>	<b>1.2 - 15.8</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 126 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	1.3	0.9	1.3	0.7 - 2.0
1998	1.0	0.0	1.0	1.0 - 1.0
1999	1.2	1.2	1.2	0.3 - 2.0
2000	1.0	0.8	1.0	0.5 - 1.5
2001	1.0	0.0	1.0	1.0 - 1.0
2002	0.8	0.8	0.8	0.0 - 1.7
2003	0.8	1.2	0.8	0.0 - 1.7
2004	0.7	1.1	1.0	0.0 - 1.7
2005	0.3	0.9	0.2	-0.5 - 1.0
2006	0.9	1.2	1.0	-0.3 - 2.0
2007	0.3	0.9	0.0	-0.2 - 0.8
2008	2.5	0.7	2.5	2.0 - 3.0
2009	1.2	0.8	1.3	0.7 - 2.0
2010	-0.4	1.3	-0.3	-1.3 - 0.5
2011	0.8	1.3	0.3	0.0 - 0.7
2012	0.7	0.6	1.0	0.0 - 1.0
2013	0.8	1.7	0.5	-0.3 - 1.0
2014	0.6	1.4	0.0	-0.3 - 2.0
2015	0.4	0.4	0.3	0.0 - 0.7
<b>Overall</b>	<b>0.8</b>	<b>1.0</b>	<b>0.7</b>	<b>0.0 - 1.3</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 127 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.0		0.0	0.0 - 0.0
1998	0.0	0.0	0.0	0.0 - 0.0
1999	1.0		1.0	1.0 - 1.0
2000	1.3	2.3	0.0	0.0 - 4.0
2001	0.4	0.5	0.3	0.0 - 1.0
2002	-0.1	0.2	0.0	-0.2 - 0.0
2003	1.7		1.7	1.7 - 1.7
2004	-0.1	1.8	0.0	-0.7 - 0.0
2005	-0.4	0.2	-0.3	-0.7 - -0.3
2006	-0.7	0.9	-0.3	-1.7 - 0.0
2007	-0.1	0.2	0.0	-0.3 - 0.0
2008	1.3	2.8	1.3	-0.7 - 3.3
2009	-0.1	1.4	-0.7	-1.0 - 0.8
2010	-0.2	0.4	0.0	-0.7 - 0.0
2011	-1.7	2.9	-0.3	-5.0 - 0.3
2012	0.0	0.6	-0.3	-0.3 - 0.7
2013	-0.8	1.5	-1.0	-2.0 - 0.5
2014	0.0	1.2	-0.3	-0.7 - 0.0
2015	0.0	0.0	0.0	0.0 - 0.0
<b>Overall</b>	<b>-0.0</b>	<b>1.3</b>	<b>0.0</b>	<b>-0.3 - 0.0</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 128 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related carcinoma *in situ* (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	4.8	0.7	4.8	4.3 - 5.3
1998	36.4	47.1	41.7	-13.0 - 80.7
1999	1.8	1.6	1.8	0.7 - 3.0
2000	8.6	8.7	6.3	2.3 - 14.8
2001	23.9	57.7	-1.7	-16.7 - 90.0
2002	11.6	31.2	-0.7	-10.7 - 27.7
2003	43.0	70.2	43.0	-6.7 - 92.7
2004	11.0	57.5	-1.0	-21.0 - 5.7
2005	-3.6	20.3	-3.2	-20.8 - 13.7
2006	-2.2	12.2	4.3	-16.3 - 5.3
2007	18.5	34.8	7.0	-1.3 - 38.3
2008	76.7	96.6	76.7	8.3 - 145.0
2009	-3.2	40.4	7.3	-39.0 - 25.7
2010	-48.3	98.6	-1.3	-99.7 - 3.2
2011	30.2	71.5	8.3	2.3 - 29.7
2012	-21.4	18.3	-31.3	-32.7 - -0.3
2013	18.5	69.8	8.0	-10.7 - 22.0
2014	-1.0	14.9	-2.7	-15.3 - 15.7
2015	20.4	53.0	-0.7	-5.7 - -0.3
<b>Overall</b>	<b>9.6</b>	<b>49.6</b>	<b>1.8</b>	<b>-10.0 - 14.2</b>

<sup>1</sup> The period for which encounters were averaged (as number per year) was 0 to 365 days after diagnosis for carcinoma *in situ*; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 129 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	7.5	10.5	6.8	1.3 - 10.6
1998	9.0	16.4	7.7	1.6 - 16.8
1999	8.9	12.1	7.3	0.7 - 14.0
2000	8.1	10.7	6.7	2.9 - 15.1
2001	8.5	15.1	10.0	2.3 - 19.3
2002	13.9	11.7	10.1	6.2 - 18.3
2003	11.2	12.6	9.9	4.5 - 16.6
2004	13.3	18.0	10.7	5.9 - 22.7
2005	11.5	14.2	10.4	5.9 - 18.7
2006	11.8	14.7	9.3	3.1 - 18.1
2007	9.2	13.9	7.7	3.1 - 15.7
2008	12.0	17.3	9.1	2.9 - 17.1
2009	10.7	13.9	8.5	5.2 - 13.8
2010	9.5	10.6	8.7	1.7 - 14.6
2011	14.5	23.3	10.9	4.4 - 17.9
2012	12.5	12.6	8.0	2.9 - 18.4
2013	9.6	16.7	9.0	2.3 - 17.2
2014	8.7	17.1	8.2	0.5 - 16.8
2015	4.7	16.0	6.1	-0.3 - 11.5
<b>Overall</b>	<b>10.2</b>	<b>15.4</b>	<b>8.8</b>	<b>3.0 - 16.7</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 130 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	1.1	1.1	0.8	0.4 - 1.7
1998	1.4	2.2	1.0	0.1 - 2.3
1999	1.2	1.0	1.0	0.4 - 1.9
2000	1.0	1.3	0.7	0.3 - 1.4
2001	1.2	1.1	0.9	0.5 - 1.6
2002	1.6	1.3	1.2	0.8 - 2.1
2003	0.9	1.2	0.7	0.3 - 1.3
2004	1.2	1.4	0.9	0.3 - 1.7
2005	1.1	1.0	0.8	0.4 - 1.9
2006	0.9	1.0	0.8	0.3 - 1.6
2007	0.9	1.3	0.8	0.4 - 1.5
2008	1.2	1.2	0.8	0.4 - 2.0
2009	1.1	1.4	0.8	0.4 - 1.3
2010	0.9	0.8	0.8	0.4 - 1.6
2011	1.0	0.9	0.7	0.4 - 1.5
2012	1.0	1.1	0.8	0.3 - 1.5
2013	0.8	1.1	0.8	0.3 - 1.2
2014	0.9	1.0	0.5	0.1 - 1.3
2015	0.7	1.1	0.4	0.1 - 1.0
<b>Overall</b>	<b>1.0</b>	<b>1.2</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 131 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.0	0.1	0.0	0.0 - 0.0
1998	0.3	1.1	0.0	-0.1 - 0.3
1999	0.7	2.2	0.0	-0.1 - 0.8
2000	0.0	0.9	-0.1	-0.4 - 0.3
2001	0.3	0.9	0.0	-0.1 - 1.0
2002	0.8	1.7	0.4	-0.1 - 1.0
2003	0.3	0.7	0.1	-0.1 - 0.4
2004	1.7	6.8	0.3	-0.1 - 1.0
2005	0.3	0.9	0.1	0.0 - 1.1
2006	0.4	1.1	0.1	-0.3 - 0.5
2007	0.1	1.1	0.0	-0.3 - 0.6
2008	0.1	1.0	0.3	-0.4 - 0.5
2009	1.0	1.9	0.4	0.0 - 1.2
2010	0.3	1.1	0.1	-0.1 - 0.5
2011	0.7	1.5	0.3	0.0 - 0.7
2012	0.7	1.3	0.1	-0.1 - 1.2
2013	1.2	3.8	0.1	-0.3 - 0.8
2014	0.1	0.6	0.0	-0.1 - 0.4
2015	-0.0	0.3	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.5</b>	<b>2.1</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 132 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to HPV-related invasive cancer (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	11.2	29.2	6.9	0.2 - 16.7
1998	12.8	22.7	9.1	1.2 - 23.2
1999	15.0	39.4	7.3	-2.8 - 27.9
2000	13.0	27.5	7.2	-2.7 - 24.2
2001	13.3	32.7	11.6	-0.7 - 22.8
2002	20.2	38.1	6.7	-0.5 - 47.6
2003	12.6	23.9	7.7	-4.8 - 26.7
2004	13.8	45.4	9.3	-11.5 - 31.9
2005	5.5	30.6	6.0	-10.4 - 28.9
2006	4.5	30.9	2.3	-7.5 - 21.2
2007	-13.4	91.1	-2.8	-27.1 - 13.5
2008	9.4	87.7	0.3	-18.9 - 28.3
2009	1.9	71.4	0.8	-13.7 - 16.9
2010	10.0	44.6	3.3	-7.9 - 16.8
2011	22.3	100.7	4.3	-6.8 - 33.1
2012	9.6	116.4	17.6	-0.9 - 40.1
2013	33.9	221.9	9.3	-3.9 - 25.6
2014	32.0	164.1	7.0	-10.1 - 22.7
2015	-0.2	49.3	-0.2	-12.9 - 12.9
<b>Overall</b>	<b>12.2</b>	<b>91.5</b>	<b>6.0</b>	<b>-7.9 - 24.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 133 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	7.1		7.1	7.1 - 7.1
1998	12.6	7.5	14.8	4.3 - 18.7
1999	14.7	15.3	14.0	-0.2 - 30.3
2000	9.6		9.6	9.6 - 9.6
2002	11.9	8.1	11.9	6.2 - 17.7
2003	10.5		10.5	10.5 - 10.5
2004	32.7	32.9	25.5	19.1 - 29.9
2005	23.6	11.1	23.6	15.7 - 31.5
2006	10.2	1.0	10.0	9.3 - 11.3
2007	21.4	19.5	13.5	6.7 - 38.8
2008	21.4	16.3	15.1	9.5 - 34.4
2009	25.8	29.2	14.9	7.6 - 44.0
2010	16.5	12.5	13.0	8.3 - 24.7
2011	8.9	7.9	10.9	4.3 - 13.5
2012	0.9	2.5	0.9	-0.8 - 2.7
2013	22.9	7.3	18.0	17.2 - 31.2
2014	1.3	50.6	21.7	-12.8 - 28.4
2015	9.1	4.1	8.1	5.2 - 12.7
<b>Overall</b>	<b>16.2</b>	<b>20.6</b>	<b>14.4</b>	<b>6.9 - 23.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 134 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	2.0		2.0	2.0 - 2.0
1998	1.9	1.7	2.4	0.0 - 3.2
1999	1.3	0.4	1.2	1.0 - 1.8
2000	1.6		1.6	1.6 - 1.6
2002	2.6	0.4	2.6	2.4 - 2.9
2003	1.6		1.6	1.6 - 1.6
2004	2.6	2.8	1.6	1.3 - 2.4
2005	1.4	0.8	1.4	0.8 - 2.0
2006	0.9	0.1	0.9	0.8 - 1.1
2007	1.8	1.7	1.6	0.4 - 3.2
2008	1.8	1.0	2.3	0.8 - 2.5
2009	3.2	3.4	2.0	1.1 - 5.4
2010	1.5	0.9	1.4	0.7 - 2.2
2011	0.7	0.7	0.6	0.3 - 1.1
2012	0.6	0.5	0.6	0.3 - 0.9
2013	2.1	1.4	1.5	1.1 - 3.6
2014	1.7	1.0	2.0	1.3 - 2.1
2015	1.3	2.0	0.7	-0.1 - 1.7
<b>Overall</b>	<b>1.8</b>	<b>1.6</b>	<b>1.4</b>	<b>0.7 - 2.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 135 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.3		0.3	0.3 - 0.3
1998	1.2	1.2	1.2	0.0 - 2.4
1999	10.2		10.2	10.2 - 10.2
2000	-0.3		-0.3	-0.3 - -0.3
2002	0.0		0.0	0.0 - 0.0
2003	0.8		0.8	0.8 - 0.8
2004	10.3	18.7	1.4	0.7 - 20.0
2005	1.5		1.5	1.5 - 1.5
2006	0.0	0.5	0.3	-0.5 - 0.4
2007	0.7	1.1	0.1	0.1 - 1.2
2008	0.6	1.0	0.6	-0.1 - 1.2
2009	3.1	4.1	1.5	0.7 - 5.5
2010	0.6	0.5	0.4	0.3 - 1.2
2011	0.9	1.5	0.4	-0.3 - 2.7
2012	0.0	0.8	0.0	-0.5 - 0.5
2013	5.4	6.9	2.6	1.0 - 9.8
2014	0.3	0.9	0.0	-0.4 - 1.2
2015	0.0	0.0	0.0	0.0 - 0.0
<b>Overall</b>	<b>2.2</b>	<b>6.2</b>	<b>0.4</b>	<b>0.0 - 1.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 136 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the anus (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	2.7		2.7	2.7 - 2.7
1998	8.8	12.7	5.1	-1.6 - 22.9
1999	78.5	85.0	32.1	26.8 - 176.7
2000	65.5		65.5	65.5 - 65.5
2002	37.4	14.5	37.4	27.1 - 47.6
2003	7.2		7.2	7.2 - 7.2
2004	77.6	76.8	66.1	18.0 - 130.8
2005	20.0	36.8	20.0	-6.0 - 46.0
2006	4.1	25.9	-0.3	-19.3 - 31.9
2007	29.9	83.4	-8.1	-23.1 - 72.8
2008	29.8	45.9	9.6	5.1 - 27.2
2009	16.4	66.2	-14.2	-18.1 - 50.9
2010	70.5	98.4	29.7	13.7 - 127.3
2011	13.8	30.8	4.9	-6.9 - 34.5
2012	100.0	128.4	100.0	9.2 - 190.8
2013	257.4	647.2	9.2	3.2 - 33.2
2014	304.1	544.9	11.6	8.8 - 353.4
2015	0.3	9.5	5.1	-10.9 - 7.5
<b>Overall</b>	<b>79.8</b>	<b>266.5</b>	<b>9.2</b>	<b>-1.5 - 46.8</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 137 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	5.4	11.0	6.8	-0.7 - 8.9
1998	8.6	12.7	3.1	0.3 - 10.8
1999	7.9	9.9	6.3	1.1 - 13.8
2000	5.2	9.1	3.5	-0.4 - 6.9
2001	6.9	12.0	4.0	-1.5 - 17.0
2002	11.9	7.8	10.8	6.3 - 16.8
2003	12.5	10.8	11.5	4.3 - 21.1
2004	13.6	9.2	10.7	7.9 - 19.2
2005	11.0	17.5	9.5	6.4 - 18.3
2006	10.7	14.7	8.7	2.7 - 22.9
2007	7.6	17.2	8.0	-2.5 - 16.3
2008	14.5	22.6	8.4	2.5 - 16.3
2009	8.1	13.2	8.0	5.3 - 11.5
2010	9.3	12.0	8.5	0.3 - 15.2
2011	16.1	34.1	12.2	3.1 - 17.6
2012	15.1	14.5	10.1	6.1 - 20.5
2013	12.8	14.4	9.2	2.9 - 15.3
2014	7.2	14.0	2.7	-0.8 - 8.1
2015	5.5	17.0	7.9	-0.8 - 13.3
<b>Overall</b>	<b>10.1</b>	<b>16.2</b>	<b>8.1</b>	<b>2.1 - 15.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 138 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	0.8	0.9	0.8	0.5 - 1.6
1998	1.4	2.8	0.8	0.1 - 1.5
1999	1.1	1.0	0.9	0.4 - 2.0
2000	0.4	0.9	0.3	0.1 - 0.6
2001	1.2	1.0	0.9	0.4 - 1.6
2002	1.3	0.7	1.1	0.7 - 1.7
2003	1.2	0.8	1.1	0.5 - 1.5
2004	1.3	1.4	1.0	0.4 - 2.0
2005	1.2	1.2	0.8	0.4 - 2.2
2006	1.1	0.9	0.9	0.4 - 1.6
2007	0.6	1.3	0.7	0.3 - 1.4
2008	1.2	1.0	0.9	0.4 - 2.1
2009	0.6	0.8	0.5	0.3 - 1.1
2010	0.9	0.8	0.8	0.4 - 1.6
2011	0.9	0.8	0.8	0.4 - 1.4
2012	1.1	1.2	0.8	0.4 - 1.2
2013	0.8	0.7	0.8	0.3 - 1.3
2014	1.0	0.8	0.8	0.4 - 1.3
2015	0.7	0.8	0.4	0.3 - 0.8
<b>Overall</b>	<b>1.0</b>	<b>1.1</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 139 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.0	0.1	0.0	0.0 - 0.0
1998	0.4	1.5	0.0	-0.1 - 0.2
1999	0.4	1.3	0.0	-0.1 - 0.8
2000	-0.1	0.8	-0.1	-0.5 - -0.1
2001	0.5	1.1	0.3	-0.1 - 1.1
2002	0.1	0.8	0.3	-0.6 - 0.8
2003	0.1	0.4	0.1	-0.1 - 0.3
2004	0.8	2.1	0.3	0.0 - 1.0
2005	0.5	0.7	0.3	0.0 - 1.2
2006	0.3	0.8	0.1	-0.1 - 0.5
2007	-0.0	0.5	-0.1	-0.4 - 0.1
2008	-0.1	0.8	0.3	-0.3 - 0.4
2009	0.4	1.0	0.4	-0.4 - 1.1
2010	0.5	1.2	0.0	0.0 - 0.4
2011	0.3	1.1	0.3	-0.1 - 0.7
2012	0.5	1.2	0.0	-0.1 - 1.2
2013	1.5	4.7	0.0	-0.5 - 1.1
2014	-0.0	0.9	0.0	-0.1 - 0.4
2015	-0.1	0.5	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.3</b>	<b>1.4</b>	<b>0.0</b>	<b>-0.1 - 0.5</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 140 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oral cavity (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	10.1	39.9	4.7	-8.9 - 15.2
1998	10.7	26.4	3.2	-4.1 - 15.6
1999	14.8	30.6	6.7	-4.9 - 27.9
2000	17.9	35.4	5.2	-2.7 - 26.3
2001	22.3	31.3	14.9	-0.7 - 29.6
2002	13.9	33.9	4.2	-11.7 - 33.5
2003	12.4	22.8	9.9	-3.9 - 27.5
2004	12.6	31.3	10.1	-8.5 - 31.9
2005	1.1	29.5	3.1	-16.7 - 22.3
2006	9.0	26.7	8.0	-6.7 - 21.2
2007	-33.0	135.9	-0.8	-21.2 - 7.1
2008	41.8	100.7	12.1	-14.0 - 57.1
2009	21.7	70.1	9.7	-12.9 - 21.9
2010	2.2	36.5	-0.4	-7.9 - 12.8
2011	30.3	155.6	11.9	-1.7 - 33.1
2012	21.9	31.8	20.6	2.8 - 33.4
2013	17.6	36.6	13.6	0.1 - 29.1
2014	2.0	56.3	2.4	-38.0 - 16.5
2015	-4.4	63.3	11.5	-19.2 - 24.4
<b>Overall</b>	<b>11.9</b>	<b>67.3</b>	<b>6.8</b>	<b>-7.9 - 25.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 141 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	6.9	7.4	6.1	1.6 - 10.5
1998	8.5	21.9	11.8	4.6 - 21.2
1999	13.7	14.5	9.9	4.3 - 21.0
2000	12.6	11.0	14.4	10.3 - 18.1
2001	9.3	19.0	11.8	6.0 - 20.8
2002	15.1	14.5	10.0	6.8 - 20.9
2003	10.2	12.8	9.9	6.3 - 15.4
2004	10.0	18.7	10.1	5.8 - 23.6
2005	12.8	9.2	11.9	6.4 - 19.1
2006	11.9	16.4	7.0	3.2 - 17.9
2007	9.1	9.6	11.2	3.7 - 13.3
2008	11.0	14.1	11.5	3.6 - 18.5
2009	11.0	9.6	9.5	5.2 - 22.3
2010	9.6	8.2	8.8	4.5 - 13.6
2011	13.5	15.0	9.3	4.8 - 17.9
2012	11.5	11.1	7.3	2.3 - 19.7
2013	7.1	18.0	5.7	1.5 - 13.5
2014	9.0	10.8	8.3	3.6 - 14.8
2015	5.1	11.8	5.2	0.1 - 10.7
<b>Overall</b>	<b>10.2</b>	<b>13.8</b>	<b>9.3</b>	<b>3.7 - 17.5</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 142 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	1.0	1.1	0.7	0.4 - 1.2
1998	1.4	1.4	1.3	0.8 - 2.3
1999	1.4	1.2	1.4	0.3 - 2.0
2000	1.4	1.7	0.8	0.5 - 1.6
2001	1.2	1.4	1.2	0.4 - 2.4
2002	1.7	1.6	1.2	0.8 - 2.1
2003	0.7	1.3	0.6	0.3 - 1.2
2004	0.8	0.9	0.6	0.2 - 1.4
2005	1.0	0.9	0.8	0.4 - 1.7
2006	0.8	1.1	0.4	0.1 - 1.3
2007	0.9	1.2	0.8	0.4 - 1.4
2008	1.2	1.6	0.8	0.1 - 1.7
2009	1.0	0.9	0.8	0.5 - 1.2
2010	0.8	0.9	0.7	0.4 - 1.2
2011	1.0	1.0	0.4	0.4 - 1.5
2012	0.9	1.1	0.7	0.3 - 1.7
2013	0.7	1.1	0.4	0.0 - 1.2
2014	0.4	0.6	0.4	-0.1 - 0.4
2015	0.5	1.0	0.4	0.0 - 0.8
<b>Overall</b>	<b>0.9</b>	<b>1.2</b>	<b>0.7</b>	<b>0.3 - 1.4</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 143 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	-0.1	0.1	0.0	-0.1 - 0.0
1998	0.1	0.2	0.0	0.0 - 0.1
1999	0.1	0.5	0.0	0.0 - 0.4
2000	0.2	1.2	0.3	-0.7 - 0.3
2001	0.2	0.8	0.0	-0.4 - 0.7
2002	1.4	2.1	0.8	0.4 - 1.7
2003	0.4	1.0	0.1	-0.1 - 0.5
2004	0.3	1.7	0.3	-0.4 - 0.4
2005	-0.0	1.0	0.0	0.0 - 0.5
2006	0.5	1.6	0.0	-0.4 - 0.5
2007	0.2	1.4	0.1	-0.1 - 1.3
2008	0.3	1.0	0.3	-0.4 - 0.5
2009	0.8	1.5	0.3	0.0 - 0.8
2010	0.2	1.1	0.1	-0.3 - 0.8
2011	0.8	1.7	0.2	0.0 - 0.5
2012	1.2	1.6	0.4	0.0 - 2.8
2013	-0.1	0.5	-0.1	-0.4 - 0.1
2014	0.1	0.6	0.0	-0.1 - 0.4
2015	0.0	0.1	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.4</b>	<b>1.2</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 144 **Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the oropharynx (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	10.0	11.2	9.9	0.9 - 12.5
1998	14.6	20.1	19.9	7.6 - 27.8
1999	11.9	37.2	14.8	1.6 - 29.2
2000	8.8	14.6	7.2	-4.8 - 16.1
2001	9.3	36.1	11.1	0.5 - 16.1
2002	21.9	43.4	6.7	2.9 - 30.4
2003	8.8	23.3	3.2	-9.2 - 16.5
2004	1.3	38.8	4.9	-10.3 - 19.4
2005	8.5	32.5	13.2	3.3 - 30.9
2006	4.3	30.3	2.4	-7.1 - 21.0
2007	0.5	42.6	0.4	-20.5 - 15.5
2008	-21.1	90.3	-7.2	-20.5 - 11.9
2009	-17.0	72.7	0.4	-12.5 - 13.0
2010	7.6	33.0	3.2	-9.2 - 14.1
2011	17.0	57.0	0.7	-6.8 - 27.1
2012	-12.8	165.8	15.3	-0.9 - 45.1
2013	-4.5	49.4	1.1	-12.3 - 18.5
2014	14.2	56.1	7.6	-8.4 - 21.7
2015	0.4	21.5	-0.4	-7.6 - 8.3
<b>Overall</b>	<b>4.1</b>	<b>58.5</b>	<b>4.9</b>	<b>-7.1 - 20.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 145 **Distribution of excess number of clinician visits<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	29.6	3.9	29.6	26.8 - 32.4
1998	12.0		12.0	12.0 - 12.0
1999	0.1	7.2	0.7	-9.3 - 6.8
2000	3.2	11.2	5.1	2.9 - 8.7
2001	9.9	10.4	6.9	5.1 - 18.5
2002	16.3	12.0	13.7	7.6 - 25.0
2003	11.4	18.4	4.7	1.3 - 32.2
2004	5.9	6.8	5.9	3.2 - 6.3
2005	-1.3	14.2	2.5	-17.0 - 10.6
2006	19.3	7.8	18.3	12.1 - 27.6
2007	2.5	4.9	4.2	-2.5 - 6.0
2008	5.0	7.3	5.7	-2.1 - 12.8
2009	-0.3	19.2	-0.3	-13.9 - 13.2
2010	-3.3	7.2	-3.3	-8.4 - 1.7
2011	18.0	20.8	7.1	4.4 - 23.7
2012	9.3	10.8	8.0	3.7 - 13.5
2013	1.9	16.1	6.9	-0.3 - 9.3
2014	12.0	12.4	12.7	6.5 - 16.8
2015	0.9	23.2	3.5	-6.7 - 11.0
<b>Overall</b>	<b>6.8</b>	<b>14.7</b>	<b>6.5</b>	<b>0.7 - 12.9</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 146 **Distribution of excess number of hospital admissions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	3.1	0.3	3.1	2.9 - 3.3
1998	0.8		0.8	0.8 - 0.8
1999	0.9	0.6	0.7	0.4 - 1.6
2000	1.4	1.0	1.2	0.7 - 1.7
2001	1.0	0.5	0.8	0.7 - 1.2
2002	2.1	1.0	2.3	1.3 - 2.9
2003	0.7	1.6	0.0	0.0 - 0.3
2004	1.2	1.0	0.9	0.5 - 1.2
2005	0.1	1.3	0.8	-1.4 - 0.9
2006	0.5	0.6	0.1	0.1 - 1.2
2007	0.8	0.5	0.7	0.5 - 1.1
2008	0.8	0.5	0.7	0.5 - 0.8
2009	2.0	0.6	2.0	1.6 - 2.4
2010	0.9	0.8	0.9	0.4 - 1.5
2011	1.2	0.8	0.8	0.7 - 1.6
2012	0.7	0.8	0.4	0.4 - 1.5
2013	0.5	0.6	0.7	0.3 - 0.8
2014	1.7	1.3	1.3	0.8 - 2.7
2015	0.9	1.1	0.5	0.0 - 1.9
<b>Overall</b>	<b>1.0</b>	<b>1.0</b>	<b>0.8</b>	<b>0.4 - 1.6</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively



Supplementary Table 147 **Distribution of excess number of ER visits<sup>1,2</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>3</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>4</sup></b>
1997	0.0		0.0	0.0 - 0.0
1998	0.3		0.3	0.3 - 0.3
1999	0.4	1.0	0.1	-0.3 - 1.0
2000	0.0	0.3	0.1	-0.2 - 0.3
2001	0.2	0.2	0.3	0.0 - 0.3
2002	0.7	1.8	0.7	-0.5 - 2.0
2003				
2004	0.3	0.4	0.4	-0.1 - 0.5
2005	-0.6		-0.6	-0.6 - -0.6
2006	0.3	0.3	0.3	0.1 - 0.5
2007	-0.5	0.4	-0.7	-0.8 - -0.0
2008	-0.3	1.1	0.0	-0.8 - 0.5
2009	1.4		1.4	1.4 - 1.4
2010	-0.9		-0.9	-0.9 - -0.9
2011	1.9	2.7	1.9	0.0 - 3.8
2012	0.0		0.0	0.0 - 0.0
2013	0.2	0.6	0.4	-0.1 - 0.7
2014	0.4	0.4	0.3	0.0 - 0.7
2015	-0.0	0.1	0.0	0.0 - 0.0
<b>Overall</b>	<b>0.2</b>	<b>0.8</b>	<b>0.0</b>	<b>-0.1 - 0.4</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>3</sup> Standard deviation; <sup>4</sup> Q1 and Q3 are the first and third quartile respectively

Supplementary Table 148 **invasive cancer of the penis Distribution of excess number of prescriptions<sup>1</sup> (per year) due to invasive cancer of the penis (for patients compared to their matches) among Manitoba males by year of diagnosis (1997-2015).**

<b>Year of diagnosis</b>	<b>Average</b>	<b>SD<sup>2</sup></b>	<b>Median</b>	<b>Q1 - Q3<sup>3</sup></b>
1997	33.9	23.1	33.9	17.6 - 50.2
1998	35.6		35.6	35.6 - 35.6
1999	-5.9	7.9	-2.8	-12.8 - 1.7
2000	4.7	26.1	3.9	-2.7 - 28.4
2001	5.4	24.9	1.6	-6.5 - 24.8
2002	27.8	37.9	30.3	-4.3 - 60.0
2003	26.7	29.4	27.7	-4.1 - 46.7
2004	3.9	27.8	-11.5	-13.6 - 10.2
2005	5.2	36.6	-14.1	-17.7 - 47.5
2006	-24.3	63.3	1.2	-96.4 - 22.3
2007	-56.1	66.2	-28.7	-99.1 - -10.4
2008	-3.7	42.6	-8.0	-32.1 - 19.2
2009	30.5	46.4	30.5	-2.4 - 63.3
2010	23.5	83.4	23.5	-35.5 - 82.5
2011	28.9	39.1	32.0	4.0 - 44.6
2012	19.7	85.1	-19.6	-29.2 - 107.5
2013	21.5	75.6	12.5	-3.9 - 25.6
2014	6.7	38.1	6.6	-19.6 - 26.4
2015	6.2	69.9	-9.1	-13.4 - 8.7
<b>Overall</b>	<b>6.3</b>	<b>50.6</b>	<b>1.2</b>	<b>-15.1 - 28.0</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) was 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> Standard deviation; <sup>3</sup> Q1 and Q3 are the first and third quartile respectively

**Attributable excess healthcare utilization**

Supplementary Table 149 **Excess number of healthcare encounters<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males according to different estimates of the attributable fraction (1997-2015)**

HPV-related disease	Total healthcare encounters	Volesky et al.[3]		Saraiya et al.[2]	
		AF <sup>2</sup>	Attributable visits	AF <sup>2</sup>	Attributable visits
<b>Excess clinician visits</b>					
Anogenital warts	67,637	100%	67,637	100%	67,637
All HPV-related carcinoma <i>in situ</i>	733	<sup>3</sup>	250	<sup>4</sup>	424
All HPV-related invasive cancers	11,665		4,876		6,823
Invasive cancer of the anus	1,167	88%	1,027	89%	1,039
Invasive cancer of the oral cavity	4,330	8%	346	33%	1,429
Invasive cancer of the oropharynx	5,224	60%	3,134	72%	3,761
Invasive cancer of the penis	943	39%	368	63%	594
<b>Total</b>	<b>80,034</b>		<b>72,763</b>		<b>74,885</b>
<b>Excess hospital admissions</b>					
Anogenital warts	2,218	100%	2,218	100%	2,218
All HPV-related carcinoma <i>in situ</i>	66	<sup>3</sup>	21	<sup>4</sup>	36
All HPV-related invasive cancers	1,174		489		688
Invasive cancer of the anus	126	88%	111	89%	113
Invasive cancer of the oral cavity	425	8%	34	33%	140
Invasive cancer of the oropharynx	478	60%	287	72%	344
Invasive cancer of the penis	145	39%	56	63%	91
<b>Total</b>	<b>3,458</b>		<b>2,728</b>		<b>2,943</b>
<b>Excess ER visits<sup>5</sup></b>					
Anogenital warts	1,118	100%	1,118	100%	1,118
All HPV-related carcinoma <i>in situ</i>	-3	<sup>3</sup>	-4	<sup>4</sup>	-4
All HPV-related invasive cancers	319		174		213

Invasive cancer of the anus	107	88%	95	89%	96
Invasive cancer of the oral cavity	88	8%	7	33%	29
Invasive cancer of the oropharynx	113	60%	68	72%	81
Invasive cancer of the penis	11	39%	4	63%	7
<b>Total</b>	<b>1,434</b>		<b>1,287</b>		<b>1,327</b>

#### Excess prescriptions

Anogenital warts	35,618	100%	35,618	100%	35,618
All HPV-related carcinoma <i>in situ</i>	811	<sup>3</sup>	297	<sup>4</sup>	479
All HPV-related invasive cancers	13,811		7,057		8,851
Invasive cancer of the anus	5,747	88%	5,057	89%	5,115
Invasive cancer of the oral cavity	5,107	8%	409	33%	1,685
Invasive cancer of the oropharynx	2,089	60%	1,253	72%	1,504
Invasive cancer of the penis	868	39%	338	63%	547
<b>Total</b>	<b>50,239</b>		<b>42,973</b>		<b>44,947</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer; <sup>2</sup> AF = Fraction of disease attributable to HPV; <sup>3</sup> Carcinoma *in situ* AF: 88% for anus, 8% for oral cavity, 60% for oropharynx, and 39% for penis; <sup>4</sup> Carcinoma *in situ* AF: 89% for anus, 33% for oral cavity, 72% for oropharynx, and 63% for penis; <sup>5</sup> ER visits are for the Winnipeg Regional Health Authority only

Supplementary Table 150 **Excess number of clinician visits<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction**

Year	Volesky et al.[3]		Saraiya et al.[2]	
	Total	Per case	Total	Per case
1997	3,870	4.73	3,942	4.81
1998	2,710	3.87	2,798	4.00
1999	2,339	3.69	2,406	3.79
2000	2,935	4.32	3,020	4.44
2001	2,945	4.48	3,043	4.62
2002	2,931	3.90	3,080	4.10
2003	3,233	4.20	3,337	4.33
2004	3,843	4.68	3,959	4.82
2005	3,425	4.00	3,519	4.11
2006	3,382	4.06	3,497	4.19
2007	4,185	5.21	4,275	5.32
2008	4,239	4.72	4,381	4.87
2009	4,096	4.50	4,217	4.63
2010	4,613	4.66	4,725	4.78
2011	5,220	5.20	5,426	5.41
2012	4,758	4.76	4,909	4.91
2013	4,323	4.80	4,424	4.91
2014	4,968	5.04	5,090	5.16
2015	4,749	4.73	4,838	4.82
<b>Total</b>	<b>72,763</b>	<b>4.54</b>	<b>74,885</b>	<b>4.67</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 151 **Excess number of hospital admissions<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction**

Year	Volesky et al.[3]		Saraiya et al.[2]	
	Total	Per case	Total	Per case
1997	220	0.27	230	0.28
1998	217	0.31	230	0.33
1999	144	0.23	154	0.24
2000	190	0.28	199	0.29
2001	177	0.27	189	0.29
2002	125	0.17	140	0.19
2003	154	0.20	163	0.21
2004	150	0.18	162	0.20
2005	133	0.16	143	0.17
2006	90	0.11	100	0.12
2007	115	0.14	125	0.16
2008	178	0.20	192	0.21
2009	122	0.13	133	0.15
2010	114	0.12	125	0.13
2011	128	0.13	141	0.14
2012	99	0.10	110	0.11
2013	113	0.13	122	0.14
2014	142	0.14	155	0.16
2015	117	0.12	130	0.13
<b>Total</b>	<b>2,728</b>	<b>0.17</b>	<b>2,943</b>	<b>0.18</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 152 **Excess number of ER visits<sup>1,2</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction**

Year	Volesky et al.[3]		Saraiya et al.[2]	
	Total	Per case	Total	Per case
1997	1	0.00	2	0.00
1998	21	0.04	23	0.04
1999	22	0.05	24	0.05
2000	94	0.20	96	0.20
2001	48	0.10	50	0.11
2002	88	0.16	91	0.17
2003	78	0.14	80	0.14
2004	161	0.28	166	0.29
2005	112	0.19	114	0.19
2006	60	0.10	62	0.10
2007	65	0.11	65	0.11
2008	90	0.14	91	0.14
2009	47	0.08	51	0.08
2010	51	0.08	54	0.08
2011	80	0.12	83	0.12
2012	71	0.11	76	0.11
2013	60	0.10	64	0.11
2014	130	0.19	131	0.19
2015	4	0.01	4	0.01
<b>Total</b>	<b>1,287</b>	<b>0.11</b>	<b>1,327</b>	<b>0.12</b>

<sup>1</sup> ER visits are for the Winnipeg Regional Health Authority only; <sup>2</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

Supplementary Table 153 **Excess number of prescriptions<sup>1</sup> (per year) due to HPV-related diseases (for patients compared to their matches) among Manitoba males by year of diagnosis according to different estimates of the attributable fraction**

Year	Volesky et al.[3]		Saraiya et al.[2]	
	Total	Per case	Total	Per case
1997	2,706	3.30	2,807	3.43
1998	2,139	3.06	2,273	3.25
1999	855	1.35	942	1.49
2000	1,961	2.88	2,087	3.07
2001	2,000	3.04	2,170	3.30
2002	1,119	1.49	1,299	1.73
2003	2,634	3.42	2,772	3.60
2004	2,376	2.89	2,481	3.02
2005	823	0.96	856	1.00
2006	659	0.79	706	0.85
2007	2,041	2.54	1,836	2.29
2008	1,321	1.47	1,527	1.70
2009	2,255	2.48	2,338	2.57
2010	2,863	2.89	2,880	2.91
2011	3,696	3.68	4,035	4.02
2012	2,378	2.38	2,492	2.49
2013	2,766	3.07	2,916	3.24
2014	4,804	4.87	4,917	4.99
2015	3,574	3.56	3,612	3.60
<b>Total</b>	<b>42,973</b>	<b>2.68</b>	<b>44,947</b>	<b>2.81</b>

<sup>1</sup> The periods for which encounters were averaged (as number per year) were 0 to 365 days after diagnosis for AGW and carcinoma *in situ* and 180 days before to 730 days after diagnosis for invasive cancer

References

1. Kliewer EV, Demers AA, Elliott L, Lotocki R, Butler JR, Brisson M. Twenty-year trends in the incidence and prevalence of diagnosed anogenital warts in Canada. *Sexually transmitted diseases*. 2009;36:380–6.
2. Saraiya M, Unger ER, Thompson TD, Lynch CF, Hernandez BY, Lyu CW, et al. US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. *J Natl Cancer Inst [Internet]*. 2015 [cited 2019 Oct 31];107. Available from: <https://academic.oup.com/jnci/article/107/6/djv086/872092>
3. Volesky KD, El-Zein M, Franco EL, Brenner DR, Friedenreich CM, Ruan Y. Cancers attributable to infections in Canada. *Preventive Medicine*. 2019;122:109–17.